Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006 Aug 15;114(7):e257–354. doi: 10.1161/circulationaha.106.177292. PMID: 16908781. [PubMed: 16908781] [CrossRef]

Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001 May 9;285(18):2370–5. PMID: 11343485. [PubMed: 11343485]

Furberg CD, Psaty BM, Manolio TA, et al. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol. 1994 Aug 1;74(3):236–41. PMID: 8037127. [PubMed: 8037127]

Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010 Feb 23;121(7):e46–e215. doi: 10.1161/circulationaha.109.192667. PMID: 20019324. [PubMed: 20019324] [CrossRef]

Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006 Jul 11;114(2):119–25. doi: 10.1161/circulationaha.105.595140. PMID: 16818816. [PubMed: 16818816] [CrossRef]

Lee WC, Lamas GA, Balu S, et al. Direct treatment cost of atrial fibrillation in the elderly American population: a Medicare perspective. J Med Econ. 2008;11(2):281–98. doi: 10.3111/13696990802063425. PMID: 19450086. [PubMed: 19450086] [CrossRef]

Thrall G, Lane D, Carroll D, et al. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med. 2006 May;119(5):448e1–19. doi: 10.1016/j.amjmed.2005.10.057. PMID: 16651058. [PubMed: 16651058] [CrossRef]

Stewart S, Hart CL, Hole DJ, et al. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002 Oct 1;113(5):359–64. PMID: 12401529. [PubMed: 12401529]

Dulli DA, Stanko H, Levine RL. Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology. 2003 Mar-Apr;22(2):118–23. doi: 10.1159/000068743. PMID: 12629277. [PubMed: 12629277] [CrossRef]

Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke. 1996 Oct;27(10):1760–4. PMID: 8841325. [PubMed: 8841325]

Paciaroni M, Agnelli G, Caso V, et al. Atrial fibrillation in patients with first-ever stroke: frequency, antithrombotic treatment before the event and effect on clinical outcome. J Thromb Haemost. 2005 Jun;3(6):1218–23. doi: 10.1111/j.1538-7836.2005.01344.x. PMID: 15892862. [PubMed: 15892862] [CrossRef]

Caro JJ. An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation. Am J Manag Care. 2004 Dec;10:(14 Suppl):S451–58; discussion S8-61. PMID: 15696909. [PubMed: 15696909]

Lopes RD, Crowley MJ, Shah BR, et al. Stroke Prevention in Atrial Fibrillation. AHRQ Comparative Effectiveness Reviews. 2013. PMID: 24049843. [PubMed: 24049843]

Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001 Jun 13;285(22):2864–70. PMID: 11401607. [PubMed: 11401607]

Inoue H, Nozawa T, Hirai T, et al. Accumulation of risk factors increases risk of thromboembolic events in patients with nonvalvular atrial fibrillation. Circ J. 2006 Jun;70(6):651–6. PMID: 16723782. [PubMed: 16723782]

Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010 Feb;137(2):263–72. doi: 10.1378/chest.09-1584. PMID: 19762550. [PubMed: 19762550] [CrossRef]

January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014 Dec 02;64(21):e1–76. doi: 10.1016/j.jacc.2014.03.022. PMID: 24685669. [PubMed: 24685669] [CrossRef]

Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010 Nov;138(5):1093–100. doi: 10.1378/chest.10-0134. PMID: 20299623. [PubMed: 20299623] [CrossRef]

Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun;133:(6 Suppl):160S–98S. doi: 10.1378/chest.08-0670. PMID: 18574265. [PubMed: 18574265] [CrossRef]

Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007 Jun 19;146(12):857–67. PMID: 17577005. [PubMed: 17577005]

Piccini JP, Hernandez AF, Zhao X, et al. Quality of care for atrial fibrillation among patients hospitalized for heart failure. J Am Coll Cardiol. 2009 Sep 29;54(14):1280–9. doi: 10.1016/j.jacc.2009.04.091. PMID: 19778670. [PubMed: 19778670] [CrossRef]

Hsu JC, Chan PS, Tang F, et al. Oral Anticoagulant Prescription in Patients With Atrial Fibrillation and a Low Risk of Thromboembolism: Insights From the NCDR PINNACLE Registry. JAMA Intern Med. 2015 Jun;175(6):1062–5. doi: 10.1001/jamainternmed.2015.0920. PMID: 25867280. [PMC free article: PMC4540345] [PubMed: 25867280] [CrossRef]

Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139–51. doi: 10.1056/NEJMoa0905561. PMID: 19717844. [PubMed: 19717844] [CrossRef]

Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8;365(10):883–91. doi: 10.1056/NEJMoa1009638. PMID: 21830957. [PubMed: 21830957] [CrossRef]

Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981–92. doi: 10.1056/NEJMoa1107039. PMID: 21870978. [PubMed: 21870978] [CrossRef]

Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 Nov 28;369(22):2093–104. doi: 10.1056/NEJMoa1310907. PMID: 24251359. [PubMed: 24251359] [CrossRef]

Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–962. doi: 10.1093/eurheartj/ehw210. [PubMed: 27567408] [CrossRef]

Agency for Healthcare Research and Quality. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville, MD: Agency for Healthcare Research and Quality. Available at: https://www​.effectivehealthcare​.ahrq.gov​/topics/cer-methods-guide/overview. Accessed November 27, 2017.

Agency for Healthcare Research and Quality. Methods Guide for Medical Test Reviews. Rockville, MD: Agency for Healthcare Research and Quality. Available at: https://www​.effectivehealthcare​.ahrq.gov​/topics/methods-guidance-tests​/overview-2012/. Accessed November 27, 2017.

Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009 Jul 21;6(7):e1000097. doi: 10.1371/journal.pmed.1000097. PMID: 19621072. [PMC free article: PMC2707599] [PubMed: 19621072] [CrossRef]

Ando G, Capranzano P. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with chronic kidney disease: A systematic review and network meta-analysis. Int J Cardiol. 2017 Mar 15;231:162–9. doi: 10.1016/j.ijcard.2016.11.303. PMID: 28007305. [PubMed: 28007305] [CrossRef]

Bai Y, Deng H, Shantsila A, et al. Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation: Systematic Review and Meta-Analysis. Stroke. 2017 Apr;48(4):970–6. doi: 10.1161/strokeaha.116.016275. PMID: 28213573. [PubMed: 28213573] [CrossRef]

Bode WD, Patel N, Gehi AK. Left atrial appendage occlusion for prevention of stroke in nonvalvular atrial fibrillation: a meta-analysis. J Interv Card Electrophysiol. 2015 Jun;43(1):79–89. doi: 10.1007/s10840-015-9988-1. PMID: 25711953. [PubMed: 25711953] [CrossRef]

Briceno DF, Villablanca P, Cyrille N, et al. Left Atrial Appendage Occlusion Device and Novel Oral Anticoagulants Versus Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Circ Arrhythm Electrophysiol. 2015 Oct;8(5):1057–64. doi: 10.1161/circep.115.002993. PMID: 26226997. [PubMed: 26226997] [CrossRef]

Bundhun PK, Soogund MZ, Teeluck AR, et al. Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2017 Jan 06;17(1):15. doi: 10.1186/s12872-016-0449-2. PMID: 28056795. [PMC free article: PMC5216587] [PubMed: 28056795] [CrossRef]

Caldeira D, Costa J, Fernandes RM, et al. Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysis. J Interv Card Electrophysiol. 2014 Sep;40(3):277–84. doi: 10.1007/s10840-014-9930-y. PMID: 25012972. [PubMed: 25012972] [CrossRef]

Chen JY, Zhang AD, Lu HY, et al. CHADS2 versus CHA2DS2-VASc score in assessing the stroke and thromboembolism risk stratification in patients with atrial fibrillation: a systematic review and meta-analysis. J Geriatr Cardiol. 2013 Sep;10(3):258–66. doi: 10.3969/j.issn.1671-5411.2013.03.004. PMID: 24133514. [PMC free article: PMC3796700] [PubMed: 24133514] [CrossRef]

Garg J, Chaudhary R, Krishnamoorthy P, et al. Safety and efficacy of oral factor-Xa inhibitors versus Vitamin K antagonist in patients with non-valvular atrial fibrillation: Meta-analysis of phase II and III randomized controlled trials. Int J Cardiol. 2016 Sep 01;218:235–9. doi: 10.1016/j.ijcard.2016.05.059. PMID: 27236121. [PubMed: 27236121] [CrossRef]

Gomez-Outes A, Terleira-Fernandez AI, Calvo-Rojas G, et al. Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups. Thrombosis. 2013;2013:640723. doi: 10.1155/2013/640723. PMID: 24455237. [PMC free article: PMC3885278] [PubMed: 24455237] [CrossRef]

Harel Z, Chertow GM, Shah PS, et al. Warfarin and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation Receiving Dialysis: A Systematic Review and Meta-analysis. Can J Cardiol. 2017 Jun;33(6):737–46. doi: 10.1016/j.cjca.2017.02.004. PMID: 28545622. [PubMed: 28545622] [CrossRef]

Holmes DR, Jr., Doshi SK, Kar S, et al. Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis. J Am Coll Cardiol. 2015 Jun 23;65(24):2614–23. doi: 10.1016/j.jacc.2015.04.025. PMID: 26088300. [PubMed: 26088300] [CrossRef]

Joundi RA, Cipriano LE, Sposato LA, et al. Ischemic Stroke Risk in Patients With Atrial Fibrillation and CHA2DS2-VASc Score of 1: Systematic Review and Meta-Analysis. Stroke. 2016 May;47(5):1364–7. doi: 10.1161/strokeaha.115.012609. PMID: 27026630. [PubMed: 27026630] [CrossRef]

Kailas SD, Thambuluru SR. Efficacy and Safety of Direct Oral Anticoagulants Compared to Warfarin in Prevention of Thromboembolic Events Among Elderly Patients with Atrial Fibrillation. Cureus. 2016 Oct 18;8(10):e836. doi: 10.7759/cureus.836. PMID: 27900231. [PMC free article: PMC5115842] [PubMed: 27900231] [CrossRef]

Koifman E, Lipinski MJ, Escarcega RO, et al. Comparison of Watchman device with new oral anti-coagulants in patients with atrial fibrillation: A network meta-analysis. Int J Cardiol. 2016 Feb 15;205:17–22. doi: 10.1016/j.ijcard.2015.11.181. PMID: 26709135. [PubMed: 26709135] [CrossRef]

Lilli A, Di Cori A, Zaca V. Thromboembolic risk and effect of oral anticoagulation according to atrial fibrillation patterns: A systematic review and meta-analysis. Clin Cardiol. 2017 May 04 doi: 10.1002/clc.22701. PMID: 28471498. [PMC free article: PMC6490401] [PubMed: 28471498] [CrossRef]

Miller CS, Dorreen A, Martel M, et al. Risk of Gastrointestinal Bleeding in Patients Taking Non-vitamin K Antagonist Oral Anticoagulants: a Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2017 Apr 27 doi: 10.1016/j.cgh.2017.04.031. PMID: 28458008. [PubMed: 28458008] [CrossRef]

Nochaiwong S, Ruengorn C, Awiphan R, et al. Efficacy and safety of warfarin in dialysis patients with atrial fibrillation: a systematic review and meta-analysis. Open Heart. 2016;3(1):e000441. doi: 10.1136/openhrt-2016-000441. PMID: 27386140. [PMC free article: PMC4916629] [PubMed: 27386140] [CrossRef]

Noelck N, Papak J, Freeman M, et al. VA Evidence-based Synthesis Program Reports. The Effectiveness of Procedures to Remove or Occlude the Left Atrial Appendage: A Systematic Review of the Evidence. Washington (DC): Department of Veterans Affairs (US); 2015. [PubMed: 27536747]

Noelck N, Papak J, Freeman M, et al. Effectiveness of Left Atrial Appendage Exclusion Procedures to Reduce the Risk of Stroke: A Systematic Review of the Evidence. Circ Cardiovasc Qual Outcomes. 2016 Jul;9(4):395–405. doi: 10.1161/circoutcomes.115.002539. PMID: 27407055. [PubMed: 27407055] [CrossRef]

Patti G, Di Gioia G, Cavallari I, et al. Safety and efficacy of nonvitamin K antagonist oral anticoagulants versus warfarin in diabetic patients with atrial fibrillation: A study-level meta-analysis of phase III randomized trials. Diabetes Metab Res Rev. 2017 Mar;33(3) doi: 10.1002/dmrr.2876. PMID: 28029216. [PubMed: 28029216] [CrossRef]

Rasmussen LH, Larsen TB, Graungaard T, et al. Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. BMJ. 2012 Nov 05;345:e7097. doi: 10.1136/bmj.e7097. PMID: 23129490. [PMC free article: PMC3489505] [PubMed: 23129490] [CrossRef]

Romero J, Husain SA, Kelesidis I, et al. Detection of left atrial appendage thrombus by cardiac computed tomography in patients with atrial fibrillation: a meta-analysis. Circ Cardiovasc Imaging. 2013 Mar 01;6(2):185–94. doi: 10.1161/circimaging.112.000153. PMID: 23406625. [PubMed: 23406625] [CrossRef]

Sahay S, Nombela-Franco L, Rodes-Cabau J, et al. Efficacy and safety of left atrial appendage closure versus medical treatment in atrial fibrillation: a network meta-analysis from randomised trials. Heart. 2017 Jan 15;103(2):139–47. doi: 10.1136/heartjnl-2016-309782. PMID: 27587437. [PubMed: 27587437] [CrossRef]

Savarese G, Giugliano RP, Rosano GM, et al. Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis. JACC Heart Fail. 2016 Nov;4(11):870–80. doi: 10.1016/j.jchf.2016.07.012. PMID: 27614940. [PubMed: 27614940] [CrossRef]

van Doorn S, Debray TPA, Kaasenbrood F, et al. Predictive performance of the CHA2DS2-VASc rule in atrial fibrillation: a systematic review and meta-analysis. J Thromb Haemost. 2017 Jun;15(6):1065–77. doi: 10.1111/jth.13690. PMID: 28375552. [PubMed: 28375552] [CrossRef]

Wei Z, Zhang X, Wu H, et al. A meta-analysis for efficacy and safety evaluation of transcatheter left atrial appendage occlusion in patients with nonvalvular atrial fibrillation. Medicine (Baltimore). 2016 Aug;95(31):e4382. doi: 10.1097/md.0000000000004382. PMID: 27495048. [PMC free article: PMC4979802] [PubMed: 27495048] [CrossRef]

Yang Y, Zhang Z, Ng CY, et al. Meta-analysis of CHADS2 Score in Predicting Atrial Fibrillation. Am J Cardiol. 2015 Aug 15;116(4):554–62. doi: 10.1016/j.amjcard.2015.05.010. PMID: 26071992. [PubMed: 26071992] [CrossRef]

Zhou X, Zhang W, Lv W, et al. Left atrial appendage occlusion in atrial fibrillation for stroke prevention: A systemic review. Int J Cardiol. 2016 Jan 15;203:55–9. doi: 10.1016/j.ijcard.2015.10.011. PMID: 26492310. [PubMed: 26492310] [CrossRef]

Zhu W, He W, Guo L, et al. The HAS-BLED Score for Predicting Major Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis. Clin Cardiol. 2015 Sep;38(9):555–61. doi: 10.1002/clc.22435. PMID: 26418409. [PMC free article: PMC6490831] [PubMed: 26418409] [CrossRef]

Zhu W, Fu L, Ding Y, et al. Meta-analysis of ATRIA versus CHA2DS2-VASc for predicting stroke and thromboembolism in patients with atrial fibrillation. Int J Cardiol. 2017 Jan 15;227:436–42. doi: 10.1016/j.ijcard.2016.11.015. PMID: 27839802. [PubMed: 27839802] [CrossRef]

Left Atrial Appendage Closure Device With Delivery System: A Health Technology Assessment. Ont Health Technol Assess Ser. 2017;17(9):1–106. PMID: 28744335. [PMC free article: PMC5515321] [PubMed: 28744335]

Bai Y, Guo SD, Deng H, et al. Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-regression analysis. Age Ageing. 2018 Jan 1;47(1):9–17. doi: 10.1093/ageing/afx103. PMID: 28985259. [PubMed: 28985259] [CrossRef]

Bansal VK, Herzog CA, Sarnak MJ, et al. Oral Anticoagulants to Prevent Stroke in Nonvalvular Atrial Fibrillation in Patients With CKD Stage 5D: An NKF-KDOQI Controversies Report. Am J Kidney Dis. 2017 Dec;70(6):859–68. doi: 10.1053/j.ajkd.2017.08.003. PMID: 28941763. [PubMed: 28941763] [CrossRef]

Bennaghmouch N, de Veer A, Bode K, et al. The Efficacy and Safety of the Use of Non-Vitamin-K Antagonist Oral Anticoagulants in Patients with Non-Valvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials. Circulation. 2017 Nov 3 doi: 10.1161/circulationaha.117.028513. PMID: 29101289. [PubMed: 29101289] [CrossRef]

Casu G, Gulizia MM, Molon G, et al. ANMCO/AIAC/SICI-GISE/SIC/SICCH Consensus Document: percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation patients: indications, patient selection, staff skills, organisation, and training. Eur Heart J Suppl. 2017 May;19(Suppl D):D333–d53. doi: 10.1093/eurheartj/sux008. PMID: 28751849. [PMC free article: PMC5520759] [PubMed: 28751849] [CrossRef]

de JRRM, Young B, Harjai K, et al. Left atrial appendage occlusion: 2016 in review. J Intervent Cardiol. 2017;30(5):448–56. doi: 10.1111/joic.12410. [PubMed: 28799239] [CrossRef]

Deitelzweig S, Farmer C, Luo X, et al. Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies. Curr Med Res Opin. 2017 Sep;33(9):1583–94. doi: 10.1080/03007995.2017.1347090. PMID: 28644048. [PubMed: 28644048] [CrossRef]

Kimachi M, Furukawa TA, Kimachi K, et al. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. Cochrane Database Syst Rev. 2017 Nov 6;11:Cd011373. doi: 10.1002/14651858.CD011373.pub2. PMID: 29105079. [PMC free article: PMC6485997] [PubMed: 29105079] [CrossRef]

Meinshausen M, Rieckert A, Renom-Guiteras A, et al. Effectiveness and patient safety of platelet aggregation inhibitors in the prevention of cardiovascular disease and ischemic stroke in older adults - a systematic review. BMC Geriatr. 2017 Oct 16;17(Suppl 1):225. doi: 10.1186/s12877-017-0572-7. PMID: 29047342. [PMC free article: PMC5647552] [PubMed: 29047342] [CrossRef]

Norby FL, Alonso A. Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation. J Comp Eff Res. 2017 Sep;6(6):549–60. doi: 10.2217/cer-2017-0025. PMID: 28737102. [PMC free article: PMC5827778] [PubMed: 28737102] [CrossRef]

Norby FL, Alonso A. Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation. Future Virology. 2017;12(9):549–60. doi: 10.2217/cer-2017-0025. [PMC free article: PMC5827778] [PubMed: 28737102] [CrossRef]

Ntaios G, Papavasileiou V, Diener HC, et al. Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: An updated systematic review and meta-analysis of randomized controlled trials. Int J Stroke. 2017 Aug;12(6):589–96. doi: 10.1177/1747493017700663. PMID: 28730948. [PubMed: 28730948] [CrossRef]

Ntaios G, Papavasileiou V, Makaritsis K, et al. Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis. Stroke. 2017 Sep;48(9):2494–503. doi: 10.1161/strokeaha.117.017549. PMID: 28716982. [PubMed: 28716982] [CrossRef]

Oertel LB, Fogerty AE. Use of direct oral anticoagulants for stroke prevention in elderly patients with nonvalvular atrial fibrillation. J Am Assoc Nurse Pract. 2017 Sep;29(9):551–61. doi: 10.1002/2327-6924.12494. PMID: 28805310. [PubMed: 28805310] [CrossRef]

Proietti M, Romanazzi I, Romiti GF, et al. Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis. Stroke. 2018 Jan;49(1):98–106. doi: 10.1161/strokeaha.117.018395. PMID: 29167388. [PubMed: 29167388] [CrossRef]

Shen JI, Turakhia MP, Winkelmayer WC. Anticoagulation for atrial fibrillation in patients on dialysis: are the benefits worth the risks? Curr Opin Nephrol Hypertens. 2012 Nov;21(6):600–6. doi: 10.1097/MNH.0b013e32835856fd. PMID: 23079746. [PMC free article: PMC4169272] [PubMed: 23079746] [CrossRef]

Sommerauer C, Schlender L, Krause M, et al. Effectiveness and safety of vitamin K antagonists and new anticoagulants in the prevention of thromboembolism in atrial fibrillation in older adults - a systematic review of reviews and the development of recommendations to reduce inappropriate prescribing. BMC Geriatr. 2017 Oct 16;17(Suppl 1):223. doi: 10.1186/s12877-017-0573-6. PMID: 29047348. [PMC free article: PMC5647558] [PubMed: 29047348] [CrossRef]

Stahl K. Ontario health technology assessment series: Left atrial appendage closure device with delivery system: A health technology assessment. Ontario Health Technology Assessment Series. 2017;17(9):1–106. [PMC free article: PMC5515321] [PubMed: 28744335]

Tsai C, Marcus LQ, Patel P, et al. Warfarin Use in Hemodialysis Patients With Atrial Fibrillation: A Systematic Review of Stroke and Bleeding Outcomes. Can J Kidney Health Dis. 2017;4:2054358117735532. doi: 10.1177/2054358117735532. PMID: 29093823. [PMC free article: PMC5652660] [PubMed: 29093823] [CrossRef]

Vuddanda V, Turagam MK, Lakkireddy D. Left Atrial Appendage Closure: Is the Strategy Enough to Lower Long-Term Stroke Risk? Current Cardiovascular Risk Reports. 2017;11(10) doi: 10.1007/s12170-017-0555-4. [CrossRef]

Wang C, Yu Y, Zhu W, et al. Comparing the ORBIT and HAS-BLED bleeding risk scores in anticoagulated atrial fibrillation patients: a systematic review and meta-analysis. Oncotarget. 2017 Dec 12;8(65):109703–11. doi: 10.18632/oncotarget.19858. PMID: 29312640. [PMC free article: PMC5752553] [PubMed: 29312640] [CrossRef]

Zhu W, Guo L, Liu F, et al. Efficacy and safety of triple versus dual antithrombotic therapy in atrial fibrillation and ischemic heart disease: a systematic review and meta-analysis. Oncotarget. 2017 Oct 6;8(46):81154–66. doi: 10.18632/oncotarget.20870. PMID: 29113375. [PMC free article: PMC5655270] [PubMed: 29113375] [CrossRef]

Zou R, Tao J, Shi W, et al. Meta-analysis of safety and efficacy for direct oral anticoagulation treatment of non-valvular atrial fibrillation in relation to renal function. Thromb Res. 2017 Dec;160:41–50. doi: 10.1016/j.thromres.2017.10.013. PMID: 29096154. [PubMed: 29096154] [CrossRef]

Zulkifly H, Lip GYH, Lane DA. Bleeding Risk Scores in Atrial Fibrillation and Venous Thromboembolism. Am J Cardiol. 2017 Oct 1;120(7):1139–45. doi: 10.1016/j.amjcard.2017.06.058. PMID: 28800833. [PubMed: 28800833] [CrossRef]

Deitelzweig S, Farmer C, Luo X, et al. Comparison of major bleeding risk in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants in the real-world setting: a network meta-analysis. Curr Med Res Opin. 2017 Dec 8:1–12. doi: 10.1080/03007995.2017.1411793. PMID: 29188721. [PubMed: 29188721] [CrossRef]

Dechartres A, Trinquart L, Boutron I, et al. Influence of trial sample size on treatment effect estimates: meta-epidemiological study. BMJ. 2013 Apr 24;346:f2304. doi: 10.1136/bmj.f2304. PMID: 23616031. [PMC free article: PMC3634626] [PubMed: 23616031] [CrossRef]

Dechartres A, Altman DG, Trinquart L, et al. Association between analytic strategy and estimates of treatment outcomes in meta-analyses. JAMA. 2014 Aug 13;312(6):623–30. doi: 10.1001/jama.2014.8166. PMID: 25117131. [PubMed: 25117131] [CrossRef]

Whiting PF, Rutjes AWS, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529–36. PMID: 22007046. [PubMed: 22007046]

Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. Available from www​.cochrane-handbook.org. The Cochrane Collaboration; 2011.

Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011 Oct 18;343:d5928. doi: 10.1136/bmj.d5928. PMID: 22008217. [PMC free article: PMC3196245] [PubMed: 22008217] [CrossRef]

Sterne JA, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016 Oct 12;355:i4919. doi: 10.1136/bmj.i4919. PMID: 27733354. [PMC free article: PMC5062054] [PubMed: 27733354] [CrossRef]

Anonymous. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http://www​.ohri.ca/programs​/clinical_epidemiology/oxford.asp. Accessed June 5, 2017.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986 Sep;7(3):177–88. [pii]. PMID: 3802833. [PubMed: 3802833]

Ohman EM, Granger CB, Harrington RA, et al. Risk stratification and therapeutic decision making in acute coronary syndromes. JAMA. 2000 Aug 16;284(7):876–8. PMID: 10938178. [PubMed: 10938178]

Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions-Agency for Healthcare Research and Quality and the Effective Health Care Program. J Clin Epidemiol. 2010 May;63(5):513–23. PMID: 19595577. [PubMed: 19595577]

Schunemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008 May 17;336(7653):1106–10. doi: 10.1136/bmj.39500.677199.AE. PMID: 18483053. [PMC free article: PMC2386626] [PubMed: 18483053] [CrossRef]

Atkins D, Chang SM, Gartlehner G, et al. Assessing applicability when comparing medical interventions: AHRQ and the Effective Health Care Program. J Clin Epidemiol. 2011 Nov;64(11):1198–207. PMID: 21463926. [PubMed: 21463926]

Abraham JM, Larson J, Chung MK, et al. Does CHA2DS2-VASc improve stroke risk stratification in postmenopausal women with atrial fibrillation? Am J Med. 2013 Dec;126(12):1143.e1–8. doi: 10.1016/j.amjmed.2013.05.023. PMID: 24139523. [PMC free article: PMC3883047] [PubMed: 24139523] [CrossRef]

Abumuaileq RR, Abu-Assi E, Lopez-Lopez A, et al. Comparison between CHA2DS2-VASc and the new R2CHADS2 and ATRIA scores at predicting thromboembolic event in non-anticoagulated and anticoagulated patients with non-valvular atrial fibrillation. BMC Cardiovasc Disord. 2015 Nov 19;15:156. doi: 10.1186/s12872-015-0149-3. PMID: 26584938. [PMC free article: PMC4653932] [PubMed: 26584938] [CrossRef]

Ad N, Henry L, Schlauch K, et al. The CHADS score role in managing anticoagulation after surgical ablation for atrial fibrillation. Ann Thorac Surg. 2010 Oct;90(4):1257–62. doi: 10.1016/j.athoracsur.2010.05.010. PMID: 20868824. [PubMed: 20868824] [CrossRef]

Allan V, Banerjee A, Shah AD, et al. Net clinical benefit of warfarin in individuals with atrial fibrillation across stroke risk and across primary and secondary care. Heart. 2017 Feb;103(3):210–8. doi: 10.1136/heartjnl-2016-309910. PMID: 27580623. [PMC free article: PMC5284481] [PubMed: 27580623] [CrossRef]

An J, Niu F, Zheng C, et al. Warfarin Management and Outcomes in Patients with Nonvalvular Atrial Fibrillation Within an Integrated Health Care System. J Manag Care Spec Pharm. 2017 Jun;23(6):700–12. doi: 10.18553/jmcp.2017.23.6.700. PMID: 28530526. [PMC free article: PMC10398296] [PubMed: 28530526] [CrossRef]

Apostolakis S, Guo Y, Lane DA, et al. Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial. Eur Heart J. 2013 Dec;34(46):3572–9. doi: 10.1093/eurheartj/eht328. PMID: 23966309. [PubMed: 23966309] [CrossRef]

Ashburner JM, Go AS, Chang Y, et al. Effect of Diabetes and Glycemic Control on Ischemic Stroke Risk in AF Patients: ATRIA Study. J Am Coll Cardiol. 2016 Jan 26;67(3):239–47. doi: 10.1016/j.jacc.2015.10.080. PMID: 26796386. [PMC free article: PMC4724056] [PubMed: 26796386] [CrossRef]

Banerjee A, Fauchier L, Vourc’h P, et al. Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. J Am Coll Cardiol. 2013 May 21;61(20):2079–87. doi: 10.1016/j.jacc.2013.02.035. PMID: 23524209. [PubMed: 23524209] [CrossRef]

Banerjee A, Fauchier L, Bernard-Brunet A, et al. Composite risk scores and composite endpoints in the risk prediction of outcomes in anticoagulated patients with atrial fibrillation. The Loire Valley Atrial Fibrillation Project. Thromb Haemost. 2014 Mar 03;111(3):549–56. doi: 10.1160/th13-12-1033. PMID: 24452108. [PubMed: 24452108] [CrossRef]

Baruch L, Gage BF, Horrow J, et al. Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified? Stroke. 2007 Sep;38(9):2459–63. doi: 10.1161/strokeaha.106.477133. PMID: 17673721. [PubMed: 17673721] [CrossRef]

Bassand JP, Accetta G, Camm AJ, et al. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J. 2016 Oct 07;37(38):2882–9. doi: 10.1093/eurheartj/ehw233. PMID: 27357359. [PMC free article: PMC5070447] [PubMed: 27357359] [CrossRef]

Beinart R, Heist EK, Newell JB, et al. Left atrial appendage dimensions predict the risk of stroke/TIA in patients with atrial fibrillation. J Cardiovasc Electrophysiol. 2011 Jan;22(1):10–5. doi: 10.1111/j.1540-8167.2010.01854.x. PMID: 20662984. [PubMed: 20662984] [CrossRef]

Bonde AN, Lip GY, Kamper AL, et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol. 2014 Dec 16;64(23):2471–82. doi: 10.1016/j.jacc.2014.09.051. PMID: 25500231. [PubMed: 25500231] [CrossRef]

Bonde AN, Lip GY, Kamper AL, et al. Renal Function and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation: An Observational Cohort Study. Stroke. 2016 Nov;47(11):2707–13. doi: 10.1161/strokeaha.116.014422. PMID: 27758943. [PubMed: 27758943] [CrossRef]

Bouillon K, Bertrand M, Maura G, et al. Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study. Lancet Haematol. 2015 Apr;2(4):e150–9. doi: 10.1016/s2352-3026(15)00027-7. PMID: 26687957. [PubMed: 26687957] [CrossRef]

Bousser MG, Bouthier J, Buller HR, et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet. 2008 Jan 26;371(9609):315–21. doi: 10.1016/s0140-6736(08)60168-3. PMID: 18294998. [PubMed: 18294998] [CrossRef]

Camm AJ, Accetta G, Al Mahmeed W, et al. Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. BMJ Open. 2017 Mar 06;7(3):e014579. doi: 10.1136/bmjopen-2016-014579. PMID: 28264833. [PMC free article: PMC5353285] [PubMed: 28264833] [CrossRef]

Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011 Mar 3;364(9):806–17. doi: 10.1056/NEJMoa1007432. PMID: 21309657. [PubMed: 21309657] [CrossRef]

Crandall MA, Horne BD, Day JD, et al. Atrial fibrillation significantly increases total mortality and stroke risk beyond that conveyed by the CHADS2 risk factors. Pacing Clin Electrophysiol. 2009 Aug;32(8):981–6. doi: 10.1111/j.1540-8159.2009.02427.x. PMID: 19659615. [PubMed: 19659615] [CrossRef]

Fang MC, Go AS, Chang Y, et al. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2008 Feb 26;51(8):810–5. doi: 10.1016/j.jacc.2007.09.065. PMID: 18294564. [PMC free article: PMC3534960] [PubMed: 18294564] [CrossRef]

Fanola CL, Giugliano RP, Ruff CT, et al. A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial. Eur Heart J. 2017 Mar 21;38(12):888–96. doi: 10.1093/eurheartj/ehw565. PMID: 28064150. [PubMed: 28064150] [CrossRef]

Fauchier L, Clementy N, Bisson A, et al. Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA2DS2-VASc Risk Factor Be Anticoagulated? Stroke. 2016 Jul;47(7):1831–6. doi: 10.1161/strokeaha.116.013253. PMID: 27231269. [PubMed: 27231269] [CrossRef]

Flaker GC, Pogue J, Yusuf S, et al. Cognitive function and anticoagulation control in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2010 May;3(3):277–83. doi: 10.1161/circoutcomes.109.884171. PMID: 20233976. [PubMed: 20233976] [CrossRef]

Forslund T, Wettermark B, Wandell P, et al. Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA(2)DS(2)VASc scores: experience from the Stockholm region. Eur J Clin Pharmacol. 2014 Dec;70(12):1477–85. doi: 10.1007/s00228-014-1739-1. PMID: 25219360. [PubMed: 25219360] [CrossRef]

Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012 Jun;33(12):1500–10. doi: 10.1093/eurheartj/ehr488. PMID: 22246443. [PubMed: 22246443] [CrossRef]

Friberg L, Benson L, Lip GY. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. Eur Heart J. 2015 Feb 01;36(5):297–306. doi: 10.1093/eurheartj/ehu139. PMID: 24722803. [PubMed: 24722803] [CrossRef]

Gupta DK, Giugliano RP, Ruff CT, et al. The Prognostic Significance of Cardiac Structure and Function in Atrial Fibrillation: The ENGAGE AF-TIMI 48 Echocardiographic Substudy. J Am Soc Echocardiogr. 2016 Jun;29(6):537–44. doi: 10.1016/j.echo.2016.03.004. PMID: 27106009. [PMC free article: PMC4893881] [PubMed: 27106009] [CrossRef]

Haas S, Ten Cate H, Accetta G, et al. Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. PLoS One. 2016;11(10):e0164076. doi: 10.1371/journal.pone.0164076. PMID: 27792741. [PMC free article: PMC5085020] [PubMed: 27792741] [CrossRef]

Hijazi Z, Lindback J, Alexander JH, et al. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J. 2016 May 21;37(20):1582–90. doi: 10.1093/eurheartj/ehw054. PMID: 26920728. [PMC free article: PMC4875560] [PubMed: 26920728] [CrossRef]

Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003 Sep 11;349(11):1019–26. doi: 10.1056/NEJMoa022913. PMID: 12968085. [PubMed: 12968085] [CrossRef]

Jun M, James MT, Ma Z, et al. Warfarin Initiation, Atrial Fibrillation, and Kidney Function: Comparative Effectiveness and Safety of Warfarin in Older Adults With Newly Diagnosed Atrial Fibrillation. Am J Kidney Dis. 2017 Jun;69(6):734–43. doi: 10.1053/j.ajkd.2016.10.018. PMID: 27998624. [PubMed: 27998624] [CrossRef]

Larsen TB, Lip GY, Skjoth F, et al. Added predictive ability of the CHA2DS2VASc risk score for stroke and death in patients with atrial fibrillation: the prospective Danish Diet, Cancer, and Health cohort study. Circ Cardiovasc Qual Outcomes. 2012 May;5(3):335–42. doi: 10.1161/circoutcomes.111.964023. PMID: 22534406. [PubMed: 22534406] [CrossRef]

Lind M, Fahlen M, Kosiborod M, et al. Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation. Thromb Res. 2012;129(1):32–5. PMID: 21851969. [PubMed: 21851969]

Link MS, Giugliano RP, Ruff CT, et al. Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). Circ Arrhythm Electrophysiol. 2017 Jan;10(1) doi: 10.1161/circep.116.004267. PMID: 28077507. [PubMed: 28077507] [CrossRef]

Lip GY, Banerjee A, Lagrenade I, et al. Assessing the Risk of Bleeding in Patients with Atrial Fibrillation: The Loire Valley Atrial Fibrillation Project. Circ Arrhythm Electrophysiol. 2012 Aug 24 doi: 10.1161/circep.112.972869. PMID: 22923275. [PubMed: 22923275] [CrossRef]

Lip GY, Connolly S, Yusuf S, et al. Modification of outcomes with aspirin or apixaban in relation to CHADS(2) and CHA(2)DS(2)-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study. Circ Arrhythm Electrophysiol. 2013 Feb;6(1):31–8. doi: 10.1161/circep.112.975847. PMID: 23390125. [PubMed: 23390125] [CrossRef]

Marijon E, Le Heuzey JY, Connolly S, et al. Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation. 2013 Nov 12;128(20):2192–201. doi: 10.1161/circulationaha.112.000491. PMID: 24016454. [PubMed: 24016454] [CrossRef]

McMurray JJ, Ezekowitz JA, Lewis BS, et al. Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial. Circ Heart Fail. 2013 May;6(3):451–60. doi: 10.1161/circheartfailure.112.000143. PMID: 23575255. [PubMed: 23575255] [CrossRef]

McAlister FA, Wiebe N, Jun M, et al. Are Existing Risk Scores for Nonvalvular Atrial Fibrillation Useful for Prediction or Risk Adjustment in Patients With Chronic Kidney Disease? Can J Cardiol. 2017 Feb;33(2):243–52. doi: 10.1016/j.cjca.2016.08.018. PMID: 27956042. [PubMed: 27956042] [CrossRef]

Morgan CL, McEwan P, Tukiendorf A, et al. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res. 2009 May;124(1):37–41. doi: 10.1016/j.thromres.2008.09.016. PMID: 19062079. [PubMed: 19062079] [CrossRef]

Nair CK, Holmberg MJ, Aronow WS, et al. Thromboembolism in patients with atrial fibrillation with and without left atrial thrombus documented by transesophageal echocardiography. Am J Ther. 2009 Sep-Oct;16(5):385–92. doi: 10.1097/MJT.0b013e3181727b42. PMID: 19955857. [PubMed: 19955857] [CrossRef]

Nielsen PB, Larsen TB, Skjoth F, et al. Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: A nationwide cohort study. Sci Rep. 2016 Jun 06;6:27410. doi: 10.1038/srep27410. PMID: 27265586. [PMC free article: PMC4893655] [PubMed: 27265586] [CrossRef]

Oldgren J, Hijazi Z, Lindback J, et al. Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. Circulation. 2016 Nov 29;134(22):1697–707. doi: 10.1161/circulationaha.116.022802. PMID: 27569438. [PubMed: 27569438] [CrossRef]

Olesen JB, Lip GY, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb Haemost. 2011 Oct;106(4):739–49. doi: 10.1160/th11-05-0364. PMID: 21789337. [PubMed: 21789337] [CrossRef]

Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124. PMID: 21282258. [PMC free article: PMC3031123] [PubMed: 21282258]

Olesen JB, Torp-Pedersen C, Hansen ML, et al. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: A nationwide cohort study. Thromb Haemost. 2012 Apr 3;107(6):1172–9. doi: 10.1160/th12-03-0175. PMID: 22473219. [PubMed: 22473219] [CrossRef]

Olesen JB, Lip GY, Lane DA, et al. Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study. Am J Med. 2012 Aug;125(8):826e13–23. doi: 10.1016/j.amjmed.2011.11.024. PMID: 22579139. [PubMed: 22579139] [CrossRef]

Olesen JB, Fauchier L, Lane DA, et al. Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest. 2012 Jan;141(1):147–53. doi: 10.1378/chest.11-0862. PMID: 21680645. [PubMed: 21680645] [CrossRef]

Orkaby AR, Ozonoff A, Reisman JI, et al. Continued Use of Warfarin in Veterans with Atrial Fibrillation After Dementia Diagnosis. J Am Geriatr Soc. 2017 Feb;65(2):249–56. doi: 10.1111/jgs.14573. PMID: 28039854. [PubMed: 28039854] [CrossRef]

Philippart R, Brunet-Bernard A, Clementy N, et al. Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project. Thromb Haemost. 2016 May 02;115(5):1056–63. doi: 10.1160/th16-01-0007. PMID: 26843425. [PubMed: 26843425] [CrossRef]

Poli D, Antonucci E, Grifoni E, et al. Stroke risk in atrial fibrillation patients on warfarin. Predictive ability of risk stratification schemes for primary and secondary prevention. Thromb Haemost. 2009 Feb;101(2):367–72. PMID: 19190823. [PubMed: 19190823]

Poli D, Testa S, Antonucci E, et al. Bleeding and stroke risk in a real-world prospective primary prevention cohort of patients with atrial fibrillation. Chest. 2011 Oct;140(4):918–24. doi: 10.1378/chest.10-3024. PMID: 21511826. [PMC free article: PMC3734882] [PubMed: 21511826] [CrossRef]

Poli D, Lip GY, Antonucci E, et al. Stroke risk stratification in a “real-world” elderly anticoagulated atrial fibrillation population. J Cardiovasc Electrophysiol. 2011 Jan;22(1):25–30. doi: 10.1111/j.1540-8167.2010.01858.x. PMID: 20653814. [PubMed: 20653814] [CrossRef]

Potpara TS, Polovina MM, Licina MM, et al. Reliable identification of “truly low” thromboembolic risk in patients initially diagnosed with “lone” atrial fibrillation: the Belgrade atrial fibrillation study. Circ Arrhythm Electrophysiol. 2012 Apr;5(2):319–26. doi: 10.1161/circep.111.966713. PMID: 22319004. [PubMed: 22319004] [CrossRef]

Proietti M, Lip GY. Major Outcomes in Atrial Fibrillation Patients with One Risk Factor: Impact of Time in Therapeutic Range Observations from the SPORTIF Trials. Am J Med. 2016 Oct;129(10):1110–6. doi: 10.1016/j.amjmed.2016.03.024. PMID: 27086494. [PubMed: 27086494] [CrossRef]

Renoux C, Coulombe J, Suissa S. Revisiting sex differences in outcomes in non-valvular atrial fibrillation: a population-based cohort study. Eur Heart J. 2017 May 14;38(19):1473–9. doi: 10.1093/eurheartj/ehw613. PMID: 28073863. [PubMed: 28073863] [CrossRef]

Rietbrock S, Heeley E, Plumb J, et al. Chronic atrial fibrillation: Incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme. Am Heart J. 2008 Jul;156(1):57–64. doi: 10.1016/j.ahj.2008.03.010. PMID: 18585497. [PubMed: 18585497] [CrossRef]

Ruff CT, Giugliano RP, Braunwald E, et al. Cardiovascular Biomarker Score and Clinical Outcomes in Patients With Atrial Fibrillation: A Subanalysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial. JAMA Cardiol. 2016 Dec 01;1(9):999–1006. doi: 10.1001/jamacardio.2016.3311. PMID: 27706467. [PubMed: 27706467] [CrossRef]

Ruiz Ortiz M, Romo E, Mesa D, et al. [Predicting embolic events in patients with nonvalvular atrial fibrillation: evaluation of the CHADS2 score in a Mediterranean population]. Rev Esp Cardiol. 2008 Jan;61(1):29–35. PMID: 18221688. [PubMed: 18221688]

Ruiz Ortiz M, Romo E, Mesa D, et al. Oral anticoagulation in nonvalvular atrial fibrillation in clinical practice: impact of CHADS(2) score on outcome. Cardiology. 2010;115(3):200–4. doi: 10.1159/000284450. PMID: 20160440. [PubMed: 20160440] [CrossRef]

Ruiz-Nodar JM, Marin F, Manzano-Fernandez S, et al. An evaluation of the CHADS2 stroke risk score in patients with atrial fibrillation who undergo percutaneous coronary revascularization. Chest. 2011;139(6):1402–9. PMID: 20864616. [PubMed: 20864616]

Ruiz-Nodar JM, Marin F, Roldan V, et al. Should We Recommend Oral Anticoagulation Therapy in Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting With a High HAS-BLED Bleeding Risk Score? Circ Cardiovasc Interv. 2012 Aug 1;5(4):459–66. doi: 10.1161/circinterventions.112.968792. PMID: 22787018. [PubMed: 22787018] [CrossRef]

Singer DE, Chang Y, Borowsky LH, et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc. 2013 Jun 21;2(3):e000250. doi: 10.1161/jaha.113.000250. PMID: 23782923. [PMC free article: PMC3698792] [PubMed: 23782923] [CrossRef]

Stoddard MF, Singh P, Dawn B, et al. Left atrial thrombus predicts transient ischemic attack in patients with atrial fibrillation. Am Heart J. 2003 Apr;145(4):676–82. doi: 10.1067/mhj.2003.91. PMID: 12679765. [PubMed: 12679765] [CrossRef]

Stollberger C, Chnupa P, Abzieher C, et al. Mortality and rate of stroke or embolism in atrial fibrillation during long-term follow-up in the embolism in left atrial thrombi (ELAT) study. Clin Cardiol. 2004 Jan;27(1):40–6. PMID: 14743856. [PMC free article: PMC6654077] [PubMed: 14743856]

Thambidorai SK, Murray RD, Parakh K, et al. Utility of transesophageal echocardiography in identification of thrombogenic milieu in patients with atrial fibrillation (an ACUTE ancillary study). Am J Cardiol. 2005 Oct 1;96(7):935–41. doi: 10.1016/j.amjcard.2005.05.051. PMID: 16188520. [PubMed: 16188520] [CrossRef]

Van Staa TP, Setakis E, Di Tanna GL, et al. A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. J Thromb Haemost. 2011 Jan;9(1):39–48. doi: 10.1111/j.1538-7836.2010.04085.x. PMID: 21029359. [PubMed: 21029359] [CrossRef]

Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA. 2003 Aug 27;290(8):1049–56. doi: 10.1001/jama.290.8.1049. PMID: 12941677. [PubMed: 12941677] [CrossRef]

Yarmohammadi H, Klosterman T, Grewal G, et al. Efficacy of the CHADS(2) scoring system to assess left atrial thrombogenic milieu risk before cardioversion of non-valvular atrial fibrillation. Am J Cardiol. 2013 Sep 01;112(5):678–83. doi: 10.1016/j.amjcard.2013.04.047. PMID: 23726178. [PubMed: 23726178] [CrossRef]

van den Ham HA, Klungel OH, Singer DE, et al. Comparative Performance of ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores Predicting Stroke in Patients With Atrial Fibrillation: Results From a National Primary Care Database. J Am Coll Cardiol. 2015 Oct 27;66(17):1851–9. doi: 10.1016/j.jacc.2015.08.033. PMID: 26493655. [PubMed: 26493655] [CrossRef]

Inohara T, Shrader P, Pieper K, et al. Association of Atrial Fibrillation Clinical Phenotypes with Treatment Patterns and Outcomes: A Multicenter Registry Study. JAMA Cardiol. 2017 Nov 12 doi: 10.1001/jamacardio.2017.4665. PMID: 29128866. [PMC free article: PMC5833527] [PubMed: 29128866] [CrossRef]

Vinereanu D, Lopes RD, Mulder H, et al. Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin. Stroke. 2017 Dec;48(12):3266–73. doi: 10.1161/strokeaha.117.017574. PMID: 29089455. [PubMed: 29089455] [CrossRef]

Hijazi Z, Lindahl B, Oldgren J, et al. Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time. J Am Heart Assoc. 2017 Jun 23;6(6) doi: 10.1161/jaha.116.004851. PMID: 28645934. [PMC free article: PMC5669148] [PubMed: 28645934] [CrossRef]

Bassand JP, Accetta G, Al Mahmeed W, et al. Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. PLoS One. 2018;13(1):e0191592. doi: 10.1371/journal.pone.0191592. PMID: 29370229. [PMC free article: PMC5784935] [PubMed: 29370229] [CrossRef]

Rivera-Caravaca JM, Roldan V, Esteve-Pastor MA, et al. Long-Term Stroke Risk Prediction in Patients With Atrial Fibrillation: Comparison of the ABC-Stroke and CHA2DS2-VASc Scores. J Am Heart Assoc. 2017 Jul 20;6(7) doi: 10.1161/jaha.117.006490. PMID: 28729407. [PMC free article: PMC5586327] [PubMed: 28729407] [CrossRef]

Rivera-Caravaca JM, Roldan V, Esteve-Pastor MA, et al. Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation. Sci Rep. 2017 Sep 21;7(1):12066. doi: 10.1038/s41598-017-11683-2. PMID: 28935868. [PMC free article: PMC5608893] [PubMed: 28935868] [CrossRef]

Phelps E, Delate T, Witt DM, et al. Effect of increased time in the therapeutic range on atrial fibrillation outcomes within a centralized anticoagulation service. Thromb Res. 2018 Feb 6;163:54–9. doi: 10.1016/j.thromres.2018.01.024. PMID: 29407629. [PubMed: 29407629] [CrossRef]

Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation. 2007 Feb 20;115(7):928–35. PMID: 17309939. [PubMed: 17309939]

O’Brien EC, Simon DN, Thomas LE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J. 2015 Dec 07;36(46):3258–64. doi: 10.1093/eurheartj/ehv476. PMID: 26424865. [PMC free article: PMC4670965] [PubMed: 26424865] [CrossRef]

Song X, Gandhi P, Gilligan AM, et al. Comparison of all-cause, stroke, and bleed-specific healthcare resource utilization among patients with non-valvular atrial fibrillation (NVAF) and newly treated with dabigatran or warfarin. Expert Rev Pharmacoecon Outcomes Res. 2017 Jul 3:1–10. doi: 10.1080/14737167.2017.1347041. PMID: 28649894. [PubMed: 28649894] [CrossRef]

Alberts M, Amatangelo M, Bauer KA, et al. Assessing Stroke and Bleeding Risk in Atrial Fibrillation. Consensus Statement on Appropriate Anticoagulant Use. Atrial Fibrillation Optimal Treatment Task Force; 2012. Available at: www​.agingresearch.org​/section/topic/atrialfibrillation​/consensusstatement. Accessed November 19, 2012.

Apostolakis S, Lane DA, Guo Y, et al. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED Bleeding Risk-Prediction Scores in Patients With Atrial Fibrillation Undergoing Anticoagulation: The AMADEUS (Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation) Study. J Am Coll Cardiol. 2012 Jul 24 doi: 10.1016/j.jacc.2012.06.019. PMID: 22858389. [PubMed: 22858389] [CrossRef]

Apostolakis S, Lane DA, Buller H, et al. Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial. Thromb Haemost. 2013 Nov;110(5):1074–9. doi: 10.1160/th13-07-0552. PMID: 24048467. [PubMed: 24048467] [CrossRef]

Aspinall SL, DeSanzo BE, Trilli LE, et al. Bleeding Risk Index in an anticoagulation clinic. Assessment by indication and implications for care. J Gen Intern Med. 2005 Nov;20(11):1008–13. doi: 10.1111/j.1525-1497.2005.0229.x. PMID: 16307625. [PMC free article: PMC1490253] [PubMed: 16307625] [CrossRef]

Barnes GD, Gu X, Haymart B, et al. The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI(2) experience. Thromb Res. 2014 Aug;134(2):294–9. doi: 10.1016/j.thromres.2014.05.034. PMID: 24929840. [PubMed: 24929840] [CrossRef]

Esteve-Pastor MA, Garcia-Fernandez A, Macias M, et al. Is the ORBIT Bleeding Risk Score Superior to the HAS-BLED Score in Anticoagulated Atrial Fibrillation Patients? Circ J. 2016 Sep 23;80(10):2102–8. doi: 10.1253/circj.CJ-16-0471. PMID: 27557850. [PubMed: 27557850] [CrossRef]

Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011 Jul 19;58(4):395–401. doi: 10.1016/j.jacc.2011.03.031. PMID: 21757117. [PMC free article: PMC3175766] [PubMed: 21757117] [CrossRef]

Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006 Mar;151(3):713–9. doi: 10.1016/j.ahj.2005.04.017. PMID: 16504638. [PubMed: 16504638] [CrossRef]

Gallego P, Roldan V, Torregrosa JM, et al. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. Circ Arrhythm Electrophysiol. 2012 Apr;5(2):312–8. doi: 10.1161/circep.111.967000. PMID: 22319005. [PubMed: 22319005] [CrossRef]

Goodman SG, Wojdyla DM, Piccini JP, et al. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol. 2014 Mar 11;63(9):891–900. doi: 10.1016/j.jacc.2013.11.013. PMID: 24315894. [PMC free article: PMC4206565] [PubMed: 24315894] [CrossRef]

Hankey GJ, Stevens SR, Piccini JP, et al. Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. Stroke. 2014 May;45(5):1304–12. doi: 10.1161/strokeaha.113.004506. PMID: 24743444. [PubMed: 24743444] [CrossRef]

Hijazi Z, Oldgren J, Lindback J, et al. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016 Jun 04;387(10035):2302–11. doi: 10.1016/s0140-6736(16)00741-8. PMID: 27056738. [PubMed: 27056738] [CrossRef]

Jaspers Focks J, van Vugt SP, Albers-Akkers MT, et al. Low performance of bleeding risk models in the very elderly with atrial fibrillation using vitamin K antagonists. J Thromb Haemost. 2016 Sep;14(9):1715–24. doi: 10.1111/jth.13361. PMID: 27172860. [PubMed: 27172860] [CrossRef]

Lip GY, Frison L, Halperin JL, et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011 Jan 11;57(2):173–80. doi: 10.1016/j.jacc.2010.09.024. PMID: 21111555. [PubMed: 21111555] [CrossRef]

Olesen JB, Lip GYH, Hansen PR, et al. Bleeding risk in ‘real world’ patients with atrial fibrillation: Comparison of two established bleeding prediction schemes in a nationwide cohort. Journal of Thrombosis and Haemostasis. 2011;9(8):1460–7. [PubMed: 21624047]

Peacock WF, Tamayo S, Patel M, et al. CHA2DS2-VASc Scores and Major Bleeding in Patients With Nonvalvular Atrial Fibrillation Who Are Receiving Rivaroxaban. Ann Emerg Med. 2017 May;69(5):541–50.e1. doi: 10.1016/j.annemergmed.2016.09.032. PMID: 27913059. [PubMed: 27913059] [CrossRef]

Proietti M, Senoo K, Lane DA, et al. Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk Scores. Sci Rep. 2016 Apr 12;6:24376. doi: 10.1038/srep24376. PMID: 27067661. [PMC free article: PMC4828703] [PubMed: 27067661] [CrossRef]

Roldan V, Marin F, Fernandez H, et al. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a ‘real world’ anticoagulated atrial fibrillation population. Chest. 2012 Jun 21 doi: 10.1378/chest.12-0608. PMID: 22722228. [PubMed: 22722228] [CrossRef]

Senoo K, Proietti M, Lane DA, et al. Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin. Am J Med. 2016 Jun;129(6):600–7. doi: 10.1016/j.amjmed.2015.10.001. PMID: 26482233. [PubMed: 26482233] [CrossRef]

Sherwood MW, Nessel CC, Hellkamp AS, et al. Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial. J Am Coll Cardiol. 2015 Dec 01;66(21):2271–81. doi: 10.1016/j.jacc.2015.09.024. PMID: 26610874. [PubMed: 26610874] [CrossRef]

Shireman TI, Mahnken JD, Howard PA, et al. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest. 2006 Nov;130(5):1390–6. doi: 10.1378/chest.130.5.1390. PMID: 17099015. [PubMed: 17099015] [CrossRef]

Rivera-Caravaca JM, Roldan V, Esteve-Pastor MA, et al. Reduced Time in Therapeutic Range and Higher Mortality in Atrial Fibrillation Patients Taking Acenocoumarol. Clin Ther. 2018 Jan;40(1):114–22. doi: 10.1016/j.clinthera.2017.11.014. PMID: 29275065. [PubMed: 29275065] [CrossRef]

Lip GYH, Skjoth F, Nielsen PB, et al. The HAS-BLED, ATRIA and ORBIT Bleeding Scores in Atrial Fibrillation Patients Using Non-Vitamin K Antagonist Oral Anticoagulants. Am J Med. 2017 Dec 21 doi: 10.1016/j.amjmed.2017.11.046. PMID: 29274754. [PubMed: 29274754] [CrossRef]

Proietti M, Hijazi Z, Andersson U, et al. Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial. J Intern Med. 2017 Oct 16 doi: 10.1111/joim.12702. PMID: 29044861. [PubMed: 29044861] [CrossRef]

Hilkens NA, Algra A, Greving JP. Predicting Major Bleeding in Ischemic Stroke Patients With Atrial Fibrillation. Stroke. 2017 Nov;48(11):3142–4. doi: 10.1161/strokeaha.117.019183. PMID: 28931618. [PubMed: 28931618] [CrossRef]

Yao X, Gersh BJ, Sangaralingham LR, et al. Comparison of the CHA2DS2-VASc, CHADS2, HAS-BLED, ORBIT, and ATRIA Risk Scores in Predicting Non-Vitamin K Antagonist Oral Anticoagulants-Associated Bleeding in Patients With Atrial Fibrillation. Am J Cardiol. 2017 Nov 1;120(9):1549–56. doi: 10.1016/j.amjcard.2017.07.051. PMID: 28844514. [PubMed: 28844514] [CrossRef]

Esteve-Pastor MA, Rivera-Caravaca JM, Roldan V, et al. Long-term bleeding risk prediction in ‘real world’ patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores. The Murcia Atrial Fibrillation Project. Thromb Haemost. 2017 Oct 5;117(10):1848–58. doi: 10.1160/th17-07-0478. PMID: 28799620. [PubMed: 28799620] [CrossRef]

Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998 Aug;105(2):91–9. PMID: 9727814. [PubMed: 9727814]

Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005 Apr;3(4):692–4. doi: 10.1111/j.1538-7836.2005.01204.x. PMID: 15842354. [PubMed: 15842354] [CrossRef]

Abraham NS, Singh S, Alexander GC, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ. 2015 Apr 24;350:h1857. doi: 10.1136/bmj.h1857. PMID: 25910928. [PMC free article: PMC4413863] [PubMed: 25910928] [CrossRef]

Abraham NS, Noseworthy PA, Yao X, et al. Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study. Gastroenterology. 2017 Apr;152(5):1014–22.e1. doi: 10.1053/j.gastro.2016.12.018. PMID: 28043907. [PubMed: 28043907] [CrossRef]

Alexander JH, Lopes RD, Thomas L, et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2014 Jan;35(4):224–32. doi: 10.1093/eurheartj/eht445. PMID: 24144788. [PubMed: 24144788] [CrossRef]

Alexander JH, Andersson U, Lopes RD, et al. Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2016 Sep 01;1(6):673–81. doi: 10.1001/jamacardio.2016.1829. PMID: 27463942. [PubMed: 27463942] [CrossRef]

Al-Khatib SM, Thomas L, Wallentin L, et al. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. Eur Heart J. 2013 Aug;34(31):2464–71. doi: 10.1093/eurheartj/eht135. PMID: 23594592. [PubMed: 23594592] [CrossRef]

Alli O, Doshi S, Kar S, et al. Quality of life assessment in the randomized PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) trial of patients at risk for stroke with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2013 Apr 30;61(17):1790–8. doi: 10.1016/j.jacc.2013.01.061. PMID: 23500276. [PubMed: 23500276] [CrossRef]

Avezum A, Lopes RD, Schulte PJ, et al. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Circulation. 2015 Aug 25;132(8):624–32. doi: 10.1161/circulationaha.114.014807. PMID: 26106009. [PubMed: 26106009] [CrossRef]

Avgil Tsadok M, Jackevicius CA, Rahme E, et al. Sex Differences in Dabigatran Use, Safety, And Effectiveness In a Population-Based Cohort of Patients With Atrial Fibrillation. Circ Cardiovasc Qual Outcomes. 2015 Nov;8(6):593–9. doi: 10.1161/circoutcomes.114.001398. PMID: 26508666. [PubMed: 26508666] [CrossRef]

Azoulay L, Dell’aniello S, Simon TA, et al. A net clinical benefit analysis of warfarin and aspirin on stroke in patients with atrial fibrillation: a nested case-control study. BMC Cardiovasc Disord. 2012 Jun 26;12(1):49. doi: 10.1186/1471-2261-12-49. PMID: 22734842. [PMC free article: PMC3444325] [PubMed: 22734842] [CrossRef]

Bahit MC, Lopes RD, Wojdyla DM, et al. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. Heart. 2017 Apr;103(8):623–8. doi: 10.1136/heartjnl-2016-309901. PMID: 27798052. [PMC free article: PMC5529964] [PubMed: 27798052] [CrossRef]

Bansilal S, Bloomgarden Z, Halperin JL, et al. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). Am Heart J. 2015 Oct;170(4):675–82.e8. doi: 10.1016/j.ahj.2015.07.006. PMID: 26386791. [PubMed: 26386791] [CrossRef]

Bengtson LGS, Lutsey PL, Chen LY, et al. Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation. J Cardiol. 2017 Jun;69(6):868–76. doi: 10.1016/j.jjcc.2016.08.010. PMID: 27889397. [PMC free article: PMC5411320] [PubMed: 27889397] [CrossRef]

Berge E, Abdelnoor M, Nakstad PH, et al. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet. 2000 Apr 8;355(9211):1205–10. PMID: 10770301. [PubMed: 10770301]

Beyer-Westendorf J, Ehlken B, Evers T. Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. Europace. 2016 Aug;18(8):1150–7. doi: 10.1093/europace/euv421. PMID: 26830891. [PubMed: 26830891] [CrossRef]

Bjorck F, Renlund H, Lip GY, et al. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation. JAMA Cardiol. 2016 May 01;1(2):172–80. doi: 10.1001/jamacardio.2016.0199. PMID: 27437888. [PubMed: 27437888] [CrossRef]

Bohula EA, Giugliano RP, Ruff CT, et al. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. Circulation. 2016 Jul 05;134(1):24–36. doi: 10.1161/circulationaha.116.022361. PMID: 27358434. [PubMed: 27358434] [CrossRef]

Brambatti M, Darius H, Oldgren J, et al. Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. Int J Cardiol. 2015 Oct 01;196:127–31. doi: 10.1016/j.ijcard.2015.05.141. PMID: 26093161. [PubMed: 26093161] [CrossRef]

Breithardt G, Baumgartner H, Berkowitz SD, et al. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J. 2014 Dec 14;35(47):3377–85. doi: 10.1093/eurheartj/ehu305. PMID: 25148838. [PMC free article: PMC4265383] [PubMed: 25148838] [CrossRef]

Breithardt G, Baumgartner H, Berkowitz SD, et al. Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban. Heart. 2016 Jul 01;102(13):1036–43. doi: 10.1136/heartjnl-2015-308120. PMID: 26888572. [PMC free article: PMC4941167] [PubMed: 26888572] [CrossRef]

Brown JD, Shewale AR, Talbert JC. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naive Nonvalvular Atrial Fibrillation. J Manag Care Spec Pharm. 2016 Nov;22(11):1319–29. doi: 10.18553/jmcp.2016.22.11.1319. PMID: 27783556. [PMC free article: PMC5751430] [PubMed: 27783556] [CrossRef]

Chun KR, Bordignon S, Urban V, et al. Left atrial appendage closure followed by 6 weeks of antithrombotic therapy: a prospective single-center experience. Heart Rhythm. 2013 Dec;10(12):1792–9. doi: 10.1016/j.hrthm.2013.08.025. PMID: 23973952. [PubMed: 23973952] [CrossRef]

Coleman CI, Tangirala M, Evers T. Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States. PLoS One. 2016;11(6):e0157769. doi: 10.1371/journal.pone.0157769. PMID: 27327275. [PMC free article: PMC4915663] [PubMed: 27327275] [CrossRef]

Coleman CI, Antz M, Bowrin K, et al. Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study. Curr Med Res Opin. 2016 Dec;32(12):2047–53. doi: 10.1080/03007995.2016.1237937. PMID: 27633045. [PubMed: 27633045] [CrossRef]

Coleman CI, Peacock WF, Antz M. Comparative Effectiveness and Safety of Apixaban and Vitamin K Antagonist Therapy in Patients with Nonvalvular Atrial Fibrillation Treated in Routine German Practice. Heart Lung Circ. 2017 May 03 doi: 10.1016/j.hlc.2017.04.002. PMID: 28528780. [PubMed: 28528780] [CrossRef]

Connolly S, Yusuf S, Budaj A, et al. Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. Am Heart J. 2006 Jun;151(6):1187–93. doi: 10.1016/j.ahj.2005.06.026. PMID: 16781218. [PubMed: 16781218] [CrossRef]

Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006 Jun 10;367(9526):1903–12. doi: 10.1016/s0140-6736(06)68845-4. PMID: 16765759. [PubMed: 16765759] [CrossRef]

Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009 May 14;360(20):2066–78. doi: 10.1056/NEJMoa0901301. PMID: 19336502. [PubMed: 19336502] [CrossRef]

Connolly SJ, Wallentin L, Ezekowitz MD, et al. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation. 2013 Jul 16;128(3):237–43. doi: 10.1161/circulationaha.112.001139. PMID: 23770747. [PubMed: 23770747] [CrossRef]

Coppens M, Synhorst D, Eikelboom JW, et al. Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial. Eur Heart J. 2014 Jul 21;35(28):1856–63. doi: 10.1093/eurheartj/ehu048. PMID: 24569032. [PubMed: 24569032] [CrossRef]

Cowper PA, Sheng S, Lopes RD, et al. Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol. 2017 May 01;2(5):525–34. doi: 10.1001/jamacardio.2017.0065. PMID: 28355434. [PMC free article: PMC5814979] [PubMed: 28355434] [CrossRef]

De Caterina R, Andersson U, Alexander JH, et al. History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. Am Heart J. 2016 May;175:175–83. doi: 10.1016/j.ahj.2016.01.005. PMID: 27179738. [PubMed: 27179738] [CrossRef]

Deambrosis P, Bettiol A, Bolcato J, et al. Real-practice thromboprophylaxis in atrial fibrillation. Acta Pharm. 2017 Jun 27;67(2):227–36. doi: 10.1515/acph-2017-0016. PMID: 28590907. [PubMed: 28590907] [CrossRef]

Deitelzweig S, Bruno A, Trocio J, et al. An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants. Curr Med Res Opin. 2016;32(3):573–82. doi: 10.1185/03007995.2015.1131676. PMID: 26652179. [PubMed: 26652179] [CrossRef]

DeVore AD, Hellkamp AS, Becker RC, et al. Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF. Europace. 2016 Aug;18(8):1135–42. doi: 10.1093/europace/euv404. PMID: 27174904. [PMC free article: PMC4974633] [PubMed: 27174904] [CrossRef]

Diener HC, Connolly SJ, Ezekowitz MD, et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol. 2010 Dec;9(12):1157–63. doi: 10.1016/s1474-4422(10)70274-x. PMID: 21059484. [PubMed: 21059484] [CrossRef]

Lawrence J, Pogue J, Synhorst D, et al. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol. 2012 Mar;11(3):225–31. doi: 10.1016/s1474-4422(12)70017-0. PMID: 22305462. [PubMed: 22305462] [CrossRef]

Durheim MT, Cyr DD, Lopes RD, et al. Chronic obstructive pulmonary disease in patients with atrial fibrillation: Insights from the ARISTOTLE trial. Int J Cardiol. 2016 Jan 01;202:589–94. doi: 10.1016/j.ijcard.2015.09.062. PMID: 26447668. [PubMed: 26447668] [CrossRef]

Easton JD, Lopes RD, Bahit MC, et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol. 2012 Jun;11(6):503–11. doi: 10.1016/s1474-4422(12)70092-3. PMID: 22572202. [PubMed: 22572202] [CrossRef]

Eikelboom JW, O’Donnell M, Yusuf S, et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J. 2010 Mar;159(3):348–53e1. doi: 10.1016/j.ahj.2009.08.026. PMID: 20211294. [PubMed: 20211294] [CrossRef]

Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011 May 31;123(21):2363–72. doi: 10.1161/circulationaha.110.004747. PMID: 21576658. [PubMed: 21576658] [CrossRef]

Eikelboom JW, Connolly SJ, Gao P, et al. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. J Stroke Cerebrovasc Dis. 2012 Aug;21(6):429–35. doi: 10.1016/j.jstrokecerebrovasdis.2012.05.007. PMID: 22818021. [PubMed: 22818021] [CrossRef]

Eikelboom JW, Connolly SJ, Hart RG, et al. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation. J Am Coll Cardiol. 2013 Sep 03;62(10):900–8. doi: 10.1016/j.jacc.2013.05.042. PMID: 23770182. [PubMed: 23770182] [CrossRef]

Eisen A, Giugliano RP, Ruff CT, et al. Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial. Am Heart J. 2016 Feb;172:144–51. doi: 10.1016/j.ahj.2015.11.004. PMID: 26856226. [PubMed: 26856226] [CrossRef]

Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007 Nov 1;100(9):1419–26. doi: 10.1016/j.amjcard.2007.06.034. PMID: 17950801. [PubMed: 17950801] [CrossRef]

Ezekowitz MD, Connolly S, Parekh A, et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J. 2009 May;157(5):805–10, 10e1–2. doi: 10.1016/j.ahj.2009.02.005. PMID: 19376304. [PubMed: 19376304] [CrossRef]

Ezekowitz JA, Lewis BS, Lopes RD, et al. Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. Eur Heart J Cardiovasc Pharmacother. 2015 Apr;1(2):86–94. doi: 10.1093/ehjcvp/pvu024. PMID: 27533976. [PubMed: 27533976] [CrossRef]

Figini F, Mazzone P, Regazzoli D, et al. Left atrial appendage closure: A single center experience and comparison of two contemporary devices. Catheter Cardiovasc Interv. 2017 Mar 01;89(4):763–72. doi: 10.1002/ccd.26678. PMID: 27567013. [PubMed: 27567013] [CrossRef]

Flaker GC, Eikelboom JW, Shestakovska O, et al. Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial. Stroke. 2012 Dec;43(12):3291–7. doi: 10.1161/strokeaha.112.664144. PMID: 23033347. [PubMed: 23033347] [CrossRef]

Fonseca E, Sander SD, Hess GP, et al. Hospital Admissions, Costs, and 30-Day Readmissions Among Newly Diagnosed Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran Etexilate or Warfarin. J Manag Care Spec Pharm. 2015 Nov;21(11):1039–53. doi: 10.18553/jmcp.2015.21.11.1039. PMID: 26521116. [PMC free article: PMC10397811] [PubMed: 26521116] [CrossRef]

Fordyce CB, Hellkamp AS, Lokhnygina Y, et al. On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF. Circulation. 2016 Jul 05;134(1):37–47. doi: 10.1161/circulationaha.116.021890. PMID: 27358435. [PubMed: 27358435] [CrossRef]

Forslund T, Wettermark B, Hjemdahl P. Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation. Eur J Clin Pharmacol. 2016 Mar;72(3):329–38. doi: 10.1007/s00228-015-1983-z. PMID: 26613954. [PubMed: 26613954] [CrossRef]

Forslund T, Wettermark B, Andersen M, et al. Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study. Europace. 2017 Feb 10 doi: 10.1093/europace/euw416. PMID: 28177459. [PubMed: 28177459] [CrossRef]

Fosbol EL, Wang TY, Li S, et al. Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction. Am Heart J. 2012 Apr;163(4):720–8. doi: 10.1016/j.ahj.2012.01.017. PMID: 22520540. [PubMed: 22520540] [CrossRef]

Fountain RB, Holmes DR, Chandrasekaran K, et al. The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation) trial. Am Heart J. 2006 May;151(5):956–61. doi: 10.1016/j.ahj.2006.02.005. PMID: 16644311. [PubMed: 16644311] [CrossRef]

Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011 Oct;32(19):2387–94. doi: 10.1093/eurheartj/ehr342. PMID: 21873708. [PubMed: 21873708] [CrossRef]

Frost L, Johnsen SP, Pedersen L, et al. Atrial fibrillation or flutter and stroke: a Danish population-based study of the effectiveness of oral anticoagulation in clinical practice. J Intern Med. 2002 Jul;252(1):64–9. PMID: 12074740. [PubMed: 12074740]

Geller BJ, Giugliano RP, Braunwald E, et al. Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial. Am Heart J. 2015 Oct;170(4):669–74. doi: 10.1016/j.ahj.2015.06.020. PMID: 26386790. [PubMed: 26386790] [CrossRef]

Giner-Soriano M, Roso-Llorach A, Vedia Urgell C, et al. Effectiveness and safety of drugs used for stroke prevention in a cohort of non-valvular atrial fibrillation patients from a primary care electronic database. Pharmacoepidemiol Drug Saf. 2017 Jan;26(1):97–107. doi: 10.1002/pds.4137. PMID: 27868275. [PubMed: 27868275] [CrossRef]

Giugliano RP, Ruff CT, Rost NS, et al. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48. Stroke. 2014 Aug;45(8):2372–8. doi: 10.1161/strokeaha.114.006025. PMID: 24947287. [PubMed: 24947287] [CrossRef]

Gloekler S, Shakir S, Doblies J, et al. Early results of first versus second generation Amplatzer occluders for left atrial appendage closure in patients with atrial fibrillation. Clin Res Cardiol. 2015 Aug;104(8):656–65. doi: 10.1007/s00392-015-0828-1. PMID: 25736061. [PubMed: 25736061] [CrossRef]

Gorst-Rasmussen A, Lip GY, Bjerregaard Larsen T. Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care. Pharmacoepidemiol Drug Saf. 2016 Nov;25(11):1236–44. doi: 10.1002/pds.4034. PMID: 27229855. [PubMed: 27229855] [CrossRef]

Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015 Jan 13;131(2):157–64. doi: 10.1161/circulationaha.114.012061. PMID: 25359164. [PubMed: 25359164] [CrossRef]

Graham DJ, Reichman ME, Wernecke M, et al. Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation. JAMA Intern Med. 2016 Nov 01;176(11):1662–71. doi: 10.1001/jamainternmed.2016.5954. PMID: 27695821. [PubMed: 27695821] [CrossRef]

Guimaraes PO, Wojdyla DM, Alexander JH, et al. Anticoagulation therapy and clinical outcomes in patients with recently diagnosed atrial fibrillation: Insights from the ARISTOTLE trial. Int J Cardiol. 2017 Jan 15;227:443–9. doi: 10.1016/j.ijcard.2016.11.014. PMID: 27852444. [PubMed: 27852444] [CrossRef]

Halperin JL, Hankey GJ, Wojdyla DM, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014 Jul 08;130(2):138–46. doi: 10.1161/circulationaha.113.005008. PMID: 24895454. [PubMed: 24895454] [CrossRef]

Halvorsen S, Atar D, Yang H, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014 Jul 21;35(28):1864–72. doi: 10.1093/eurheartj/ehu046. PMID: 24561548. [PMC free article: PMC4104493] [PubMed: 24561548] [CrossRef]

Halvorsen S, Ghanima W, Fride Tvete I, et al. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. Eur Heart J Cardiovasc Pharmacother. 2017 Jan;3(1):28–36. doi: 10.1093/ehjcvp/pvw031. PMID: 27680880. [PMC free article: PMC5216196] [PubMed: 27680880] [CrossRef]

Hankey GJ, Patel MR, Stevens SR, et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol. 2012 Apr;11(4):315–22. doi: 10.1016/s1474-4422(12)70042-x. PMID: 22402056. [PubMed: 22402056] [CrossRef]

Hansen ML, Sorensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010 Sep 13;170(16):1433–41. doi: 10.1001/archinternmed.2010.271. PMID: 20837828. [PubMed: 20837828] [CrossRef]

Hart RG, Bhatt DL, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial. Cerebrovasc Dis. 2008;25(4):344–7. doi: 10.1159/000118380. PMID: 18303254. [PubMed: 18303254] [CrossRef]

Hart RG, Diener HC, Yang S, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke. 2012 Jun;43(6):1511–7. doi: 10.1161/strokeaha.112.650614. PMID: 22492518. [PubMed: 22492518] [CrossRef]

Healey JS, Hart RG, Pogue J, et al. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). Stroke. 2008 May;39(5):1482–6. doi: 10.1161/strokeaha.107.500199. PMID: 18323500. [PubMed: 18323500] [CrossRef]

Healey JS, Eikelboom J, Douketis J, et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation. 2012 Jul 17;126(3):343–8. doi: 10.1161/circulationaha.111.090464. PMID: 22700854. [PubMed: 22700854] [CrossRef]

Held C, Hylek EM, Alexander JH, et al. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. Eur Heart J. 2015 May 21;36(20):1264–72. doi: 10.1093/eurheartj/ehu463. PMID: 25499871. [PubMed: 25499871] [CrossRef]

Hijazi Z, Hohnloser SH, Oldgren J, et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation. 2014 Mar 04;129(9):961–70. doi: 10.1161/circulationaha.113.003628. PMID: 24323795. [PubMed: 24323795] [CrossRef]

Hijazi Z, Hohnloser SH, Andersson U, et al. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol. 2016 Jul 01;1(4):451–60. doi: 10.1001/jamacardio.2016.1170. PMID: 27438322. [PubMed: 27438322] [CrossRef]

Hobbs FD, Roalfe AK, Lip GY, et al. Performance of stroke risk scores in older people with atrial fibrillation not taking warfarin: comparative cohort study from BAFTA trial. BMJ. 2011;342:d3653. PMID: 21700651. [PMC free article: PMC3121229] [PubMed: 21700651]

Hohnloser SH, Pajitnev D, Pogue J, et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. J Am Coll Cardiol. 2007 Nov 27;50(22):2156–61. doi: 10.1016/j.jacc.2007.07.076. PMID: 18036454. [PubMed: 18036454] [CrossRef]

Hohnloser SH, Oldgren J, Yang S, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation. 2012 Feb 7;125(5):669–76. doi: 10.1161/circulationaha.111.055970. PMID: 22215856. [PubMed: 22215856] [CrossRef]

Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012 Aug 29 doi: 10.1093/eurheartj/ehs274. PMID: 22933567. [PubMed: 22933567] [CrossRef]

Hohnloser SH, Basic E, Nabauer M. Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study. Clin Res Cardiol. 2017 Mar 14 doi: 10.1007/s00392-017-1098-x. PMID: 28293797. [PubMed: 28293797] [CrossRef]

Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009 Aug 15;374(9689):534–42. doi: 10.1016/s0140-6736(09)61343-x. PMID: 19683639. [PubMed: 19683639] [CrossRef]

Holmes DR, Jr., Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014 Jul 08;64(1):1–12. doi: 10.1016/j.jacc.2014.04.029. PMID: 24998121. [PubMed: 24998121] [CrossRef]

Hu PT, Lopes RD, Stevens SR, et al. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial. J Am Heart Assoc. 2017 Jan 17;6(1) doi: 10.1161/jaha.116.004699. PMID: 28096100. [PMC free article: PMC5523640] [PubMed: 28096100] [CrossRef]

Hylek EM, Held C, Alexander JH, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol. 2014 May 27;63(20):2141–7. doi: 10.1016/j.jacc.2014.02.549. PMID: 24657685. [PubMed: 24657685] [CrossRef]

Johnson ME, Lefevre C, Collings SL, et al. Early real-world evidence of persistence on oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a cohort study in UK primary care. BMJ Open. 2016 Sep 26;6(9):e011471. doi: 10.1136/bmjopen-2016-011471. PMID: 27678530. [PMC free article: PMC5051466] [PubMed: 27678530] [CrossRef]

Laliberte F, Cloutier M, Nelson WW, et al. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin. 2014 Jul;30(7):1317–25. doi: 10.1185/03007995.2014.907140. PMID: 24650301. [PubMed: 24650301] [CrossRef]

Laliberte F, Cloutier M, Crivera C, et al. Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched users. Clin Ther. 2015 Mar 01;37(3):554–62. doi: 10.1016/j.clinthera.2015.02.001. PMID: 25749196. [PubMed: 25749196] [CrossRef]

Lamberts M, Staerk L, Olesen JB, et al. Major Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients. J Am Heart Assoc. 2017 Feb 14;6(2) doi: 10.1161/jaha.116.004517. PMID: 28196815. [PMC free article: PMC5523754] [PubMed: 28196815] [CrossRef]

Lane DA, Kamphuisen PW, Minini P, et al. Bleeding risk in patients with atrial fibrillation: the AMADEUS study. Chest. 2011 Jul;140(1):146–55. doi: 10.1378/chest.10-3270. PMID: 21415134. [PubMed: 21415134] [CrossRef]

Larsen TB, Rasmussen LH, Gorst-Rasmussen A, et al. Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study. Am J Med. 2014 Dec;127(12):1172–8.e5. doi: 10.1016/j.amjmed.2014.07.023. PMID: 25193361. [PubMed: 25193361] [CrossRef]

Larsen TB, Gorst-Rasmussen A, Rasmussen LH, et al. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. Am J Med. 2014 Jul;127(7):650–6.e5. doi: 10.1016/j.amjmed.2014.01.031. PMID: 24530792. [PubMed: 24530792] [CrossRef]

Larsen TB, Skjoth F, Nielsen PB, et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2016 Jun 16;353:i3189. doi: 10.1136/bmj.i3189. PMID: 27312796. [PMC free article: PMC4910696] [PubMed: 27312796] [CrossRef]

Lauffenburger JC, Farley JF, Gehi AK, et al. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study. J Am Heart Assoc. 2015 Apr 10;4(4) doi: 10.1161/jaha.115.001798. PMID: 25862791. [PMC free article: PMC4579955] [PubMed: 25862791] [CrossRef]

Lauw MN, Eikelboom JW, Coppens M, et al. Effects of dabigatran according to age in atrial fibrillation. Heart. 2017 Jul;103(13):1015–23. doi: 10.1136/heartjnl-2016-310358. PMID: 28213368. [PubMed: 28213368] [CrossRef]

Lee CJ, Pallisgaard JL, Olesen JB, et al. Antithrombotic Therapy and First Myocardial Infarction in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2017 Jun 20;69(24):2901–9. doi: 10.1016/j.jacc.2017.04.033. PMID: 28619189. [PubMed: 28619189] [CrossRef]

Leef G, Qin D, Althouse A, et al. Risk of Stroke and Death in Atrial Fibrillation by Type of Anticoagulation: A Propensity-Matched Analysis. Pacing Clin Electrophysiol. 2015 Nov;38(11):1310–6. doi: 10.1111/pace.12695. PMID: 26171564. [PubMed: 26171564] [CrossRef]

Li XS, Deitelzweig S, Keshishian A, et al. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice. A propensity-matched analysis of 76,940 patients. Thromb Haemost. 2017 Jun 02;117(6):1072–82. doi: 10.1160/th17-01-0068. PMID: 28300870. [PMC free article: PMC6291856] [PubMed: 28300870] [CrossRef]

Lin J, Trocio J, Gupta K, et al. Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting. J Med Econ. 2017 Jun 22:1–10. doi: 10.1080/13696998.2017.1341902. PMID: 28604139. [PubMed: 28604139] [CrossRef]

Lip GY, Eikelboom J, Yusuf S, et al. Modification of outcomes with aspirin or apixaban in relation to female and male sex in patients with atrial fibrillation: a secondary analysis of the AVERROES study. Stroke. 2014 Jul;45(7):2127–30. doi: 10.1161/strokeaha.114.005746. PMID: 24916911. [PubMed: 24916911] [CrossRef]

Lip GY, Skjoth F, Nielsen PB, et al. Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. Thromb Haemost. 2015 Oct;114(4):826–34. doi: 10.1160/th15-07-0565. PMID: 26223245. [PubMed: 26223245] [CrossRef]

Lip GY, Skjoth F, Rasmussen LH, et al. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. J Am Coll Cardiol. 2015 Apr 14;65(14):1385–94. doi: 10.1016/j.jacc.2015.01.044. PMID: 25770314. [PubMed: 25770314] [CrossRef]

Lip GY, Pan X, Kamble S, et al. Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real-world” observational study in the United States. Int J Clin Pract. 2016 Sep;70(9):752–63. doi: 10.1111/ijcp.12863. PMID: 27550177. [PMC free article: PMC5129572] [PubMed: 27550177] [CrossRef]

Lip GYH, Keshishian A, Kamble S, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin: A propensity score matched analysis. Thromb Haemost. 2016;116(5):975–86. doi: 10.1160/TH16-05-0403. [PubMed: 27538358] [CrossRef]

Lip GYH, Skjoth F, Nielsen PB, et al. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study. JAMA Cardiol. 2017 Jun 14 doi: 10.1001/jamacardio.2017.1883. PMID: 28614582. [PMC free article: PMC5710590] [PubMed: 28614582] [CrossRef]

Lopes RD, Alexander JH, Al-Khatib SM, et al. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010 Mar;159(3):331–9. doi: 10.1016/j.ahj.2009.07.035. PMID: 20211292. [PubMed: 20211292] [CrossRef]

Lopes RD, Al-Khatib SM, Wallentin L, et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet. 2012 Oct 1 doi: 10.1016/s0140-6736(12)60986-6. PMID: 23036896. [PubMed: 23036896] [CrossRef]

Lopes RD, Guimaraes PO, Kolls BJ, et al. Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. Blood. 2017 Jun 01;129(22):2980–7. doi: 10.1182/blood-2016-08-731638. PMID: 28356246. [PubMed: 28356246] [CrossRef]

Lorenzoni R, Lazzerini G, Cocci F, et al. Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) pilot study. Am Heart J. 2004 Jul;148(1):e6. doi: 10.1016/j.ahj.2004.02.008. PMID: 15215815. [PubMed: 15215815] [CrossRef]

Magnani G, Giugliano RP, Ruff CT, et al. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48. Eur J Heart Fail. 2016 Sep;18(9):1153–61. doi: 10.1002/ejhf.595. PMID: 27349698. [PubMed: 27349698] [CrossRef]

Mahaffey KW, Wojdyla D, Hankey GJ, et al. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial. Ann Intern Med. 2013 Jun 18;158(12):861–8. doi: 10.7326/0003-4819-158-12-201306180-00003. PMID: 23778903. [PubMed: 23778903] [CrossRef]

Mahaffey KW, Stevens SR, White HD, et al. Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. Eur Heart J. 2014 Jan;35(4):233–41. doi: 10.1093/eurheartj/eht428. PMID: 24132190. [PMC free article: PMC3896862] [PubMed: 24132190] [CrossRef]

Mant JW, Richards SH, Hobbs FD, et al. Protocol for Birmingham Atrial Fibrillation Treatment of the Aged study (BAFTA): a randomised controlled trial of warfarin versus aspirin for stroke prevention in the management of atrial fibrillation in an elderly primary care population [ISRCTN89345269]. BMC Cardiovasc Disord. 2003 Aug 26;3:9. doi: 10.1186/1471-2261-3-9. PMID: 12939169. [PMC free article: PMC201020] [PubMed: 12939169] [CrossRef]

Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007 Aug 11;370(9586):493–503. doi: 10.1016/s0140-6736(07)61233-1. PMID: 17693178. [PubMed: 17693178] [CrossRef]

Mar Contreras Muruaga MD, Vivancos J, Reig G, et al. Satisfaction, quality of life and perception of patients regarding burdens and benefits of vitamin K antagonists compared with direct oral anticoagulants in patients with nonvalvular atrial fibrillation. J Comp Eff Res. 2017 Mar 29 doi: 10.2217/cer-2016-0078. PMID: 28353372. [PubMed: 28353372] [CrossRef]

Martinez C, Katholing A, Wallenhorst C, et al. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Thromb Haemost. 2016 Jan;115(1):31–9. doi: 10.1160/th15-04-0350. PMID: 26246112. [PubMed: 26246112] [CrossRef]

Mavaddat N, Roalfe A, Fletcher K, et al. Warfarin versus aspirin for prevention of cognitive decline in atrial fibrillation: randomized controlled trial (Birmingham Atrial Fibrillation Treatment of the Aged Study). Stroke. 2014 May;45(5):1381–6. doi: 10.1161/strokeaha.113.004009. PMID: 24692475. [PubMed: 24692475] [CrossRef]

Monaco L, Biagi C, Conti V, et al. Safety profile of the direct oral anticoagulants: an analysis of the WHO database of adverse drug reactions. Br J Clin Pharmacol. 2017 Jul;83(7):1532–43. doi: 10.1111/bcp.13234. PMID: 28071818. [PMC free article: PMC5465343] [PubMed: 28071818] [CrossRef]

Monz BU, Connolly SJ, Korhonen M, et al. Assessing the impact of dabigatran and warfarin on health-related quality of life: results from an RE-LY sub-study. Int J Cardiol. 2013 Oct 03;168(3):2540–7. doi: 10.1016/j.ijcard.2013.03.059. PMID: 23664436. [PubMed: 23664436] [CrossRef]

Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011 Jan 18;123(2):131–6. doi: 10.1161/circulationaha.110.977546. PMID: 21200007. [PubMed: 21200007] [CrossRef]

Nelson WW, Song X, Coleman CI, et al. Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation. Curr Med Res Opin. 2014 Dec;30(12):2461–9. doi: 10.1185/03007995.2014.933577. PMID: 24926732. [PubMed: 24926732] [CrossRef]

Ng KH, Shestakovska O, Connolly SJ, et al. Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. Age Ageing. 2016 Jan;45(1):77–83. doi: 10.1093/ageing/afv156. PMID: 26590293. [PubMed: 26590293] [CrossRef]

Nielsen PB, Skjoth F, Sogaard M, et al. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2017 Feb 10;356:j510. doi: 10.1136/bmj.j510. PMID: 28188243. [PMC free article: PMC5421446] [PubMed: 28188243] [CrossRef]

Noseworthy PA, Yao X, Abraham NS, et al. Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation. Chest. 2016 Dec;150(6):1302–12. doi: 10.1016/j.chest.2016.07.013. PMID: 27938741. [PubMed: 27938741] [CrossRef]

O’Donnell MJ, Eikelboom JW, Yusuf S, et al. Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study. Am Heart J. 2016 Aug;178:145–50. doi: 10.1016/j.ahj.2016.03.019. PMID: 27502862. [PubMed: 27502862] [CrossRef]

O’Donoghue ML, Ruff CT, Giugliano RP, et al. Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillationdagger. Eur Heart J. 2015 Jun 14;36(23):1470–7. doi: 10.1093/eurheartj/ehv014. PMID: 25687352. [PubMed: 25687352] [CrossRef]

Oldgren J, Alings M, Darius H, et al. Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS2 Score: A Subgroup Analysis of the RE-LY Trial. Ann Intern Med. 2011 Nov 15;155(10):660–7. doi: 10.1059/0003-4819-155-10-201111150-00004. PMID: 22084332. [PubMed: 22084332] [CrossRef]

Orgel R, Wojdyla D, Huberman D, et al. Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). Circ Cardiovasc Qual Outcomes. 2017 May;10(5) doi: 10.1161/circoutcomes.116.003520. PMID: 28495674. [PMC free article: PMC5485838] [PubMed: 28495674] [CrossRef]

Patel MR, Hellkamp AS, Lokhnygina Y, et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). J Am Coll Cardiol. 2013 Feb 12;61(6):651–8. doi: 10.1016/j.jacc.2012.09.057. PMID: 23391196. [PubMed: 23391196] [CrossRef]

Piccini JP, Hellkamp AS, Lokhnygina Y, et al. Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. J Am Heart Assoc. 2014 Apr 22;3(2):e000521. doi: 10.1161/jaha.113.000521. PMID: 24755148. [PMC free article: PMC4187517] [PubMed: 24755148] [CrossRef]

Pillarisetti J, Reddy YM, Gunda S, et al. Endocardial (Watchman) vs epicardial (Lariat) left atrial appendage exclusion devices: Understanding the differences in the location and type of leaks and their clinical implications. Heart Rhythm. 2015 Jul;12(7):1501–7. doi: 10.1016/j.hrthm.2015.03.020. PMID: 25778430. [PubMed: 25778430] [CrossRef]

Pokorney SD, Piccini JP, Stevens SR, et al. Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. J Am Heart Assoc. 2016 Mar 08;5(3):e002197. doi: 10.1161/jaha.115.002197. PMID: 26955859. [PMC free article: PMC4943233] [PubMed: 26955859] [CrossRef]

Rash A, Downes T, Portner R, et al. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing. 2007 Mar;36(2):151–6. doi: 10.1093/ageing/afl129. PMID: 17175564. [PubMed: 17175564] [CrossRef]

Reddy VY, Doshi SK, Sievert H, et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. Circulation. 2013 Feb 12;127(6):720–9. doi: 10.1161/circulationaha.112.114389. PMID: 23325525. [PubMed: 23325525] [CrossRef]

Reddy VY, Sievert H, Halperin J, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA. 2014 Nov 19;312(19):1988–98. doi: 10.1001/jama.2014.15192. PMID: 25399274. [PubMed: 25399274] [CrossRef]

Rost NS, Giugliano RP, Ruff CT, et al. Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). Stroke. 2016 Aug;47(8):2075–82. doi: 10.1161/strokeaha.116.013540. PMID: 27387994. [PubMed: 27387994] [CrossRef]

Ruff CT, Giugliano RP, Braunwald E, et al. Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial. J Am Coll Cardiol. 2014 Aug 12;64(6):576–84. doi: 10.1016/j.jacc.2014.05.028. PMID: 25104527. [PubMed: 25104527] [CrossRef]

Ruff CT, Giugliano RP, Braunwald E, et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015 Jun 06;385(9984):2288–95. doi: 10.1016/s0140-6736(14)61943-7. PMID: 25769361. [PubMed: 25769361] [CrossRef]

Schmid M, Gloekler S, Saguner AM, et al. Transcatheter left atrial appendage closure in patients with atrial fibrillation. Kardiovaskulare Medizin. 2013;16(4):123–30.

Seeger JD, Bykov K, Bartels DB, et al. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thromb Haemost. 2015 Nov 25;114(6):1277–89. doi: 10.1160/th15-06-0497. PMID: 26446507. [PubMed: 26446507] [CrossRef]

Seeger JD, Bykov K, Bartels DB, et al. Propensity Score Weighting Compared to Matching in a Study of Dabigatran and Warfarin. Drug Saf. 2017;40(2):169–81. doi: 10.1007/s40264-016-0480-3. [PubMed: 27900668] [CrossRef]

Shah R, Hellkamp A, Lokhnygina Y, et al. Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. Am Heart J. 2016 Sep;179:77–86. doi: 10.1016/j.ahj.2016.05.019. PMID: 27595682. [PubMed: 27595682] [CrossRef]

Sherwood MW, Cyr DD, Jones WS, et al. Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial. JACC Cardiovasc Interv. 2016 Aug 22;9(16):1694–702. doi: 10.1016/j.jcin.2016.05.039. PMID: 27539689. [PMC free article: PMC6921699] [PubMed: 27539689] [CrossRef]

Shireman TI, Howard PA, Kresowik TF, et al. Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke. 2004 Oct;35(10):2362–7. doi: 10.1161/01.STR.0000141933.75462.c2. PMID: 15331796. [PubMed: 15331796] [CrossRef]

Staerk L, Gislason GH, Lip GY, et al. Risk of gastrointestinal adverse effects of dabigatran compared with warfarin among patients with atrial fibrillation: a nationwide cohort study. Europace. 2015 Aug;17(8):1215–22. doi: 10.1093/europace/euv119. PMID: 25995392. [PubMed: 25995392] [CrossRef]

Staerk L, Fosbol EL, Lip GYH, et al. Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study. Eur Heart J. 2017 Mar 21;38(12):907–15. doi: 10.1093/eurheartj/ehw496. PMID: 27742807. [PubMed: 27742807] [CrossRef]

Steffel J, Giugliano RP, Braunwald E, et al. Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis. J Am Coll Cardiol. 2016 Sep 13;68(11):1169–78. doi: 10.1016/j.jacc.2016.06.034. PMID: 27609678. [PubMed: 27609678] [CrossRef]

Stellbrink C, Nixdorff U, Hofmann T, et al. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation. 2004 Mar 2;109(8):997–1003. doi: 10.1161/01.cir.0000120509.64740.dc. PMID: 14967716. [PubMed: 14967716] [CrossRef]

Tentschert S, Parigger S, Dorda V, et al. Recurrent vascular events in patients with ischemic stroke/TIA and atrial fibrillation in relation to secondary prevention at hospital discharge. Wien Klin Wochenschr. 2004 Dec 30;116(24):834–8. PMID: 15690967. [PubMed: 15690967]

van Diepen S, Hellkamp AS, Patel MR, et al. Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF. Circ Heart Fail. 2013 Jul;6(4):740–7. doi: 10.1161/circheartfailure.113.000212. PMID: 23723250. [PubMed: 23723250] [CrossRef]

Vaughan Sarrazin MS, Jones M, Mazur A, et al. Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran. Am J Med. 2014 Dec;127(12):1179–85. doi: 10.1016/j.amjmed.2014.07.024. PMID: 25107386. [PMC free article: PMC7437526] [PubMed: 25107386] [CrossRef]

Vemmos KN, Tsivgoulis G, Spengos K, et al. Primary prevention of arterial thromboembolism in the oldest old with atrial fibrillation-a randomized pilot trial comparing adjusted-dose and fixed low-dose coumadin with aspirin. Eur J Intern Med. 2006 Jan;17(1):48–52. doi: 10.1016/j.ejim.2005.08.005. PMID: 16378886. [PubMed: 16378886] [CrossRef]

Vemulapalli S, Hellkamp AS, Jones WS, et al. Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the ROCKET AF Trial. Am Heart J. 2016 Aug;178:74–84. doi: 10.1016/j.ahj.2016.05.001. PMID: 27502854. [PubMed: 27502854] [CrossRef]

Verdecchia P, Reboldi G, Angeli F, et al. Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation- the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study. Europace. 2017 May 17 doi: 10.1093/europace/eux022. PMID: 28520924. [PMC free article: PMC5834147] [PubMed: 28520924] [CrossRef]

Viles-Gonzalez J, Kar S, Douglas P, et al. The Clinical Impact of Incomplete Left Atrial Appendage Closure With the Watchman Device in Patients with Atrial Fibrillation: A PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) Substudy. J Am Coll Cardiol. 2012;59(10):923–9. [PubMed: 22381428]

Villines TC, Schnee J, Fraeman K, et al. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Thromb Haemost. 2015 Nov 25;114(6):1290–8. doi: 10.1160/th15-06-0453. PMID: 26446456. [PubMed: 26446456] [CrossRef]

Vinereanu D, Stevens SR, Alexander JH, et al. Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. Eur Heart J. 2015 Dec 07;36(46):3268–75. doi: 10.1093/eurheartj/ehv447. PMID: 26371113. [PubMed: 26371113] [CrossRef]

Wallentin L, Lopes RD, Hanna M, et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation. 2013 Jun 04;127(22):2166–76. doi: 10.1161/circulationaha.112.142158. PMID: 23640971. [PubMed: 23640971] [CrossRef]

Weir MR, Berger JS, Ashton V, et al. Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence. Curr Med Res Opin. 2017 Jun 07:1–30. doi: 10.1080/03007995.2017.1339674. PMID: 28590785. [PubMed: 28590785] [CrossRef]

Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010 Sep;104(3):633–41. doi: 10.1160/th10-01-0066. PMID: 20694273. [PubMed: 20694273] [CrossRef]

Westenbrink BD, Alings M, Granger CB, et al. Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J. 2017 Mar;185:140–9. doi: 10.1016/j.ahj.2016.12.008. PMID: 28267467. [PubMed: 28267467] [CrossRef]

Xu H, Ruff CT, Giugliano RP, et al. Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial. J Am Heart Assoc. 2016 Feb 23;5(2) doi: 10.1161/jaha.115.002587. PMID: 26908401. [PMC free article: PMC4802446] [PubMed: 26908401] [CrossRef]

Yamashita T, Koretsune Y, Yang Y, et al. Edoxaban vs. Warfarin in East Asian Patients With Atrial Fibrillation- An ENGAGE AF-TIMI 48 Subanalysis. Circ J. 2016;80(4):860–9. doi: 10.1253/circj.CJ-15-1082. PMID: 26888149. [PubMed: 26888149] [CrossRef]

Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation. J Am Heart Assoc. 2016 Jun 13;5(6) doi: 10.1161/jaha.116.003725. PMID: 27412905. [PMC free article: PMC4937291] [PubMed: 27412905] [CrossRef]

Yigit Z, Kucukoglu MS, Okcun B, et al. The safety of low-molecular weight heparins for the prevention of thromboembolic events after cardioversion of atrial fibrillation. Jpn Heart J. 2003 May;44(3):369–77. PMID: 12825804. [PubMed: 12825804]

Perera KS, Pearce LA, Sharma M, et al. Predictors of Mortality in Patients With Atrial Fibrillation (from the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events [ACTIVE A]). Am J Cardiol. 2017 Dec 11 doi: 10.1016/j.amjcard.2017.11.028. PMID: 29291887. [PubMed: 29291887] [CrossRef]

Jain R, Fu AC, Lim J, et al. Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States. J Manag Care Spec Pharm. 2018 Jan;24(1):73–82. doi: 10.18553/jmcp.2018.24.1.73. PMID: 29290177. [PMC free article: PMC10398022] [PubMed: 29290177] [CrossRef]

Proietti M, Lip GYH. Impact of quality of anticoagulation control on outcomes in patients with atrial fibrillation taking aspirin: An analysis from the SPORTIF trials. Int J Cardiol. 2018 Feb 1;252:96–100. doi: 10.1016/j.ijcard.2017.10.091. PMID: 29249444. [PubMed: 29249444] [CrossRef]

Paciaroni M, Agnelli G, Falocci N, et al. Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non-Vitamin-K Oral Anticoagulants (RAF-NOACs) Study. J Am Heart Assoc. 2017 Nov 29;6(12) doi: 10.1161/jaha.117.007034. PMID: 29220330. [PMC free article: PMC5779022] [PubMed: 29220330] [CrossRef]

Go AS, Singer DE, Toh S, et al. Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort Study. Ann Intern Med. 2017 Dec 19;167(12):845–54. doi: 10.7326/m16-1157. PMID: 29132153. [PubMed: 29132153] [CrossRef]

Rao MP, Vinereanu D, Wojdyla DM, et al. Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial. Am J Med. 2017 Nov 6 doi: 10.1016/j.amjmed.2017.10.036. PMID: 29122636. [PubMed: 29122636] [CrossRef]

Reddy VY, Doshi SK, Kar S, et al. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. J Am Coll Cardiol. 2017 Dec 19;70(24):2964–75. doi: 10.1016/j.jacc.2017.10.021. PMID: 29103847. [PubMed: 29103847] [CrossRef]

Deitelzweig S, Luo X, Gupta K, et al. Effect of Apixaban Versus Warfarin Use on Health Care Resource Utilization and Costs Among Elderly Patients with Nonvalvular Atrial Fibrillation. J Manag Care Spec Pharm. 2017 Nov;23(11):1191–201. doi: 10.18553/jmcp.2017.17060. PMID: 29083968. [PMC free article: PMC10397614] [PubMed: 29083968] [CrossRef]

Amin A, Keshishian A, Vo L, et al. Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for non-valvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan. J Med Econ. 2017 Nov 20:1–10. doi: 10.1080/13696998.2017.1394866. PMID: 29047304. [PubMed: 29047304] [CrossRef]

Denas G, Gennaro N, Ferroni E, et al. Effectiveness and safety of oral anticoagulation with non-vitamin K antagonists compared to well-managed vitamin K antagonists in naive patients with non-valvular atrial fibrillation: Propensity score matched cohort study. Int J Cardiol. 2017 Dec 15;249:198–203. doi: 10.1016/j.ijcard.2017.09.029. PMID: 28935464. [PubMed: 28935464] [CrossRef]

Norby FL, Bengtson LGS, Lutsey PL, et al. Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation. BMC Cardiovasc Disord. 2017 Sep 6;17(1):238. doi: 10.1186/s12872-017-0672-5. PMID: 28874129. [PMC free article: PMC5585896] [PubMed: 28874129] [CrossRef]

Borne RT, O’Donnell C, Turakhia MP, et al. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration. BMC Cardiovasc Disord. 2017 Sep 2;17(1):236. doi: 10.1186/s12872-017-0671-6. PMID: 28865440. [PMC free article: PMC5581418] [PubMed: 28865440] [CrossRef]

Hernandez I, Zhang Y, Saba S. Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation. Am J Cardiol. 2017 Nov 15;120(10):1813–9. doi: 10.1016/j.amjcard.2017.07.092. PMID: 28864318. [PubMed: 28864318] [CrossRef]

Staerk L, Gerds TA, Lip GYH, et al. Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study. J Intern Med. 2018 Jan;283(1):45–55. doi: 10.1111/joim.12683. PMID: 28861925. [PubMed: 28861925] [CrossRef]

Brown JD, Shewale AR, Talbert JC. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment-Naive Atrial Fibrillation Patients: An Update Using 2013-2014 Data. J Manag Care Spec Pharm. 2017 Sep;23(9):958–67. doi: 10.18553/jmcp.2017.23.9.958. PMID: 28854077. [PMC free article: PMC5747360] [PubMed: 28854077] [CrossRef]

Adeboyeje G, Sylwestrzak G, Barron JJ, et al. Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation. J Manag Care Spec Pharm. 2017 Sep;23(9):968–78. doi: 10.18553/jmcp.2017.23.9.968. PMID: 28854073. [PMC free article: PMC10398327] [PubMed: 28854073] [CrossRef]

Deitelzweig S, Luo X, Gupta K, et al. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients. Curr Med Res Opin. 2017 Oct;33(10):1745–54. doi: 10.1080/03007995.2017.1334638. PMID: 28849676. [PubMed: 28849676] [CrossRef]

Mueller T, Alvarez-Madrazo S, Robertson C, et al. Use of direct oral anticoagulants in patients with atrial fibrillation in Scotland: Applying a coherent framework to drug utilisation studies. Pharmacoepidemiol Drug Saf. 2017 Nov;26(11):1378–86. doi: 10.1002/pds.4272. PMID: 28752670. [PMC free article: PMC5697642] [PubMed: 28752670] [CrossRef]

Melloni C, Dunning A, Granger CB, et al. Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial. Am J Med. 2017 Dec;130(12):1440–8.e1. doi: 10.1016/j.amjmed.2017.06.026. PMID: 28739198. [PubMed: 28739198] [CrossRef]

Sjogren V, Bystrom B, Renlund H, et al. Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study. PLoS One. 2017;12(7):e0181000. doi: 10.1371/journal.pone.0181000. PMID: 28700711. [PMC free article: PMC5507293] [PubMed: 28700711] [CrossRef]

Coleman CI, Peacock WF, Bunz TJ, et al. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack. Stroke. 2017 Aug;48(8):2142–9. doi: 10.1161/strokeaha.117.017474. PMID: 28655814. [PubMed: 28655814] [CrossRef]

Reynolds SL, Ghate SR, Sheer R, et al. Healthcare utilization and costs for patients initiating Dabigatran or Warfarin. Health Qual Life Outcomes. 2017 Jun 21;15(1):128. doi: 10.1186/s12955-017-0705-x. PMID: 28637460. [PMC free article: PMC5480105] [PubMed: 28637460] [CrossRef]

Douros A, Renoux C, Coulombe J, et al. Patterns of long-term use of non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation: Quebec observational study. Pharmacoepidemiology and Drug Safety. 2017;26(12):1546–54. doi: 10.1002/pds.4333. [PubMed: 28984052] [CrossRef]

Amin A, Keshishian A, Trocio J, et al. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population. Curr Med Res Opin. 2017;33(9):1595–604. doi: 10.1080/03007995.2017.1345729. [PubMed: 28635338] [CrossRef]

Chrischilles EA, Gagne JJ, Fireman B, et al. Prospective surveillance pilot of rivaroxaban safety within the US Food and Drug Administration Sentinel System. Pharmacoepidemiol Drug Saf. 2018 Jan 10 doi: 10.1002/pds.4375. PMID: 29318683. [PubMed: 29318683] [CrossRef]

Collings SL, Vannier-Moreau V, Johnson ME, et al. Initiation and continuation of oral anticoagulant prescriptions for stroke prevention in non-valvular atrial fibrillation: A cohort study in primary care in France. Arch Cardiovasc Dis. 2018 Feb 2 doi: 10.1016/j.acvd.2017.10.003. PMID: 29398546. [PubMed: 29398546] [CrossRef]

Hohnloser SH, Basic E, Hohmann C, et al. Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon: Data from 61,000 Patients with Atrial Fibrillation. Thromb Haemost. 2018 Jan 22 doi: 10.1160/th17-10-0733. PMID: 29359278. [PubMed: 29359278] [CrossRef]

Kochar A, Hellkamp AS, Lokhnygina Y, et al. Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trial. Clin Cardiol. 2018 Jan;41(1):39–45. doi: 10.1002/clc.22846. PMID: 29389037. [PMC free article: PMC6489762] [PubMed: 29389037] [CrossRef]

Li X, Keshishian A, Hamilton M, et al. Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach. PLoS One. 2018;13(1):e0191722. doi: 10.1371/journal.pone.0191722. PMID: 29373602. [PMC free article: PMC5786316] [PubMed: 29373602] [CrossRef]

Loo SY, Coulombe J, Dell’Aniello S, et al. Comparative effectiveness of novel oral anticoagulants in UK patients with non-valvular atrial fibrillation and chronic kidney disease: a matched cohort study. BMJ Open. 2018 Jan 24;8(1):e019638. doi: 10.1136/bmjopen-2017-019638. PMID: 29371284. [PMC free article: PMC5786093] [PubMed: 29371284] [CrossRef]

Shah S, Norby FL, Datta YH, et al. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation. Blood Adv. 2018 Feb 13;2(3):200–9. doi: 10.1182/bloodadvances.2017010694. PMID: 29378726. [PMC free article: PMC5812321] [PubMed: 29378726] [CrossRef]

Wang SV, Huybrechts KF, Fischer MA, et al. Generalized boosted modeling to identify subgroups where effect of dabigatran versus warfarin may differ: An observational cohort study of patients with atrial fibrillation. Pharmacoepidemiol Drug Saf. 2018 Jan 30 doi: 10.1002/pds.4395. PMID: 29383858. [PubMed: 29383858] [CrossRef]

Hijazi Z, Hohnloser SH, Oldgren J, et al. Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis. Am Heart J. 2018 doi: 10.1016/j.ahj.2017.10.015. [PubMed: 29653640] [CrossRef]

Coleman C, Yuan Z, Schein J, et al. Importance of balancing follow-up time and impact of oral-anticoagulant users’ selection when evaluating medication adherence in atrial fibrillation patients treated with rivaroxaban and apixaban. Curr Med Res Opin. 2017 Jun;33(6):1033–43. doi: 10.1080/03007995.2017.1297932. PMID: 28366075. [PubMed: 28366075] [CrossRef]

Nelson WW, Song X, Thomson E, et al. Medication persistence and discontinuation of rivaroxaban and dabigatran etexilate among patients with non-valvular atrial fibrillation. Curr Med Res Opin. 2015;31(10):1831–40. doi: 10.1185/03007995.2015.1074064. PMID: 26211816. [PubMed: 26211816] [CrossRef]

McHorney CA, Peterson ED, Laliberte F, et al. Comparison of Adherence to Rivaroxaban Versus Apixaban Among Patients With Atrial Fibrillation. Clin Ther. 2016 Nov;38(11):2477–88. doi: 10.1016/j.clinthera.2016.09.014. PMID: 27789043. [PubMed: 27789043] [CrossRef]

Larsen TB, Rasmussen LH, Gorst-Rasmussen A, et al. Myocardial ischemic events in ‘real world’ patients with atrial fibrillation treated with dabigatran or warfarin. Am J Med. 2014 Apr;127(4):329–36.e4. doi: 10.1016/j.amjmed.2013.12.005. PMID: 24361757. [PubMed: 24361757] [CrossRef]

Coleman CI, Antz M, Ehlken B, et al. REal-LIfe Evidence of stroke prevention in patients with atrial Fibrillation-The RELIEF study. Int J Cardiol. 2016 Jan 15;203:882–4. doi: 10.1016/j.ijcard.2015.09.037. PMID: 26605688. [PubMed: 26605688] [CrossRef]

Burton C, Isles C, Norrie J, et al. The safety and adequacy of antithrombotic therapy for atrial fibrillation: a regional cohort study. Br J Gen Pract. 2006 Sep;56(530):697–702. PMID: 16954003. [PMC free article: PMC1876637] [PubMed: 16954003]

Fraenkel L, Street RL, Jr., Fried TR. Development of a tool to improve the quality of decision making in atrial fibrillation. BMC Med Inform Decis Mak. 2011 Oct 06;11:59. doi: 10.1186/1472-6947-11-59. PMID: 21977943. [PMC free article: PMC3207873] [PubMed: 21977943] [CrossRef]

Lahaye S, Regpala S, Lacombe S, et al. Evaluation of patients’ attitudes towards stroke prevention and bleeding risk in atrial fibrillation. Thromb Haemost. 2014 Mar 03;111(3):465–73. doi: 10.1160/th13-05-0424. PMID: 24337399. [PubMed: 24337399] [CrossRef]

Fatima S, Holbrook A, Schulman S, et al. Development and validation of a decision aid for choosing among antithrombotic agents for atrial fibrillation. Thromb Res. 2016 Sep;145:143–8. doi: 10.1016/j.thromres.2016.06.015. PMID: 27388221. [PubMed: 27388221] [CrossRef]

Stephan LS, Almeida ED, Guimaraes RB, et al. Oral Anticoagulation in Atrial Fibrillation: Development and Evaluation of a Mobile Health Application to Support Shared Decision-Making. Arq Bras Cardiol. 2018 Jan;110(1):7–15. doi: 10.5935/abc.20170181. PMID: 29412241. [PMC free article: PMC5831296] [PubMed: 29412241] [CrossRef]

Palacio AM, Kirolos I, Tamariz L. Patient values and preferences when choosing anticoagulants. Patient Prefer Adherence. 2015;9:133–8. doi: 10.2147/ppa.s64295. PMID: 25653506. [PMC free article: PMC4309777] [PubMed: 25653506] [CrossRef]

Pandya E, Bajorek BV. Assessment of Web-based education resources informing patients about stroke prevention in atrial fibrillation. J Clin Pharm Ther. 2016 Dec;41(6):667–76. doi: 10.1111/jcpt.12446. PMID: 27704588. [PubMed: 27704588] [CrossRef]

O’Neill ES, Grande SW, Sherman A, et al. Availability of patient decision aids for stroke prevention in atrial fibrillation: A systematic review. Am Heart J. 2017 Sep;191:1–11. doi: 10.1016/j.ahj.2017.05.014. PMID: 28888264. [PubMed: 28888264] [CrossRef]

Kunneman M, Branda ME, Noseworthy PA, et al. Shared decision making for stroke prevention in atrial fibrillation: study protocol for a randomized controlled trial. Trials. 2017 Sep 29;18(1):443. doi: 10.1186/s13063-017-2178-y. PMID: 28962662. [PMC free article: PMC5622521] [PubMed: 28962662] [CrossRef]

Coylewright M, Holmes DR, Jr. Caution Regarding Government-Mandated Shared Decision Making for Patients With Atrial Fibrillation. Circulation. 2017 Jun 06;135(23):2211–3. doi: 10.1161/circulationaha.117.026285. PMID: 28584027. [PubMed: 28584027] [CrossRef]